Page last updated: 2024-12-05

ethosuximide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ethosuximide is an anticonvulsant medication primarily used to treat absence seizures. Its synthesis involves a multi-step process that begins with the reaction of diethyl malonate with ethyl chloroacetate to form ethyl 2-ethoxycarbonyl-3-oxobutanoate. This intermediate is then reacted with hydrazine to form the corresponding hydrazide, which is further cyclized to form ethosuximide. Ethosuximide is believed to exert its anticonvulsant effect by blocking T-type calcium channels in the thalamus, a brain region involved in the generation of absence seizures. Studies suggest that ethosuximide is effective in controlling absence seizures in children and adults, but its use may be associated with adverse effects, including drowsiness, dizziness, and gastrointestinal problems. Despite its potential benefits, ethosuximide is not commonly used as a first-line treatment for epilepsy due to the availability of newer and more effective anticonvulsant medications. However, it remains a valuable option for patients who do not respond to other treatments. The study of ethosuximide continues to provide insights into the mechanisms of absence seizures and the development of new anticonvulsant drugs.'

Ethosuximide: An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ethosuximide : A dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3291
CHEMBL ID696
CHEBI ID4887
SCHEMBL ID34212
SCHEMBL ID20541518
MeSH IDM0007887

Synonyms (231)

Synonym
BRD-A99633051-001-04-7
2,5-pyrrolidinedione, 3-ethyl-3-methyl-
KBIO1_000218
DIVK1C_000218
NCIOPEN2_000014
3-ethyl-3-methylpyrrolidine-2,5-dione
EU-0100532
etosuximida
thetamid
2, 3-ethyl-3-methyl-
piknolepsin
wln: t5vmvtj d2 d1
simatin
simatin(e)
zarondan
succimal
h 940
ethosuccimide
emeside
pemalin
3-ethyl-3-methyl-2,5-pyrrolidinedione
c.i. 366
3-ethyl-3-methylpyrroline-2,5-dione
cn-10,395
suxilep
mesentol
.gamma.-methyl-.gamma.-ethylsuccinimide
zarodan
2-ethyl-2-methylsuccinimide
zarontin
ronton
pemal
suximal
zartalin
succinimide, 2-ethyl-2-methyl-
asamid
etosuximid
peptinimid
nsc-64013
zaraondan
ethosuxide
pyknolepsinum
pentinimid
ethymal
suxin
zarondan-saft
ethosuccinimide
petnidan
cl 366
pm-671
ci-366
etomal
epileo petit mal
suxinutin
petinimid
atysmal
.alpha.-ethyl-.alpha.-methylsuccinimide
h-490
nsc64013
capitus
succimitin
pm 671
SPECTRUM_001385
PRESTWICK2_000165
PRESTWICK_611
cas-77-67-8
NCGC00016320-01
SPECTRUM5_001073
2, 5-pyrrolidinedione, 3-ethyl-3-methyl-
piknole.psi.n
pyknole.psi.num
3-ethyl-3-methyl-pyrrolidine-2,5-dione
3-ethyl-3-methyl-2, 5-pyrrolidinedione
LOPAC0_000532
BPBIO1_000033
AB00052288
ethosuximide
C07505
77-67-8
thilopemal
3-ethyl-3-methylsuccinimide
3-methyl-3-ethylsuccinimide
(+/-)-2-ethyl-2-methylsuccinimide
2-methyl-2-ethylsuccinimide
gamma-methyl-gamma-ethyl-succinimide
DB00593
alpha-ethyl-alpha-methylsuccinimide
3-methyl-3-ethylpyrrolidine-2,5-dione
gamma-ethyl-gamma-methyl-succinimide
alpha-methyl-alpha-ethylsuccinimide
zarontin (tn)
ethosuximide (jp17/usp/inn)
D00539
BSPBIO_000029
PRESTWICK3_000165
NCGC00093923-03
NCGC00093923-02
(+-)-2-ethyl-2-methylsuccinimide
ethylmethylsuccimide
ci 366
einecs 201-048-7
2,5-pyrrolidinedione, 3-ethyl-3-methyl-, (+-)-
nsc 64013
n-ethyl methylsuccinimide
ethosuccimid
etosuximide
brn 0117054
etosuximida [inn-spanish]
aethosuximide [german]
etosuccimide [dcit]
hsdb 1119
aethosuccimidum
ethosuximidum [inn-latin]
KBIO2_007001
KBIO2_004433
KBIOSS_001865
KBIOGR_001342
KBIO2_001865
KBIO3_002008
SPECTRUM4_001051
SPBIO_001465
SPECTRUM3_000944
NINDS_000218
PRESTWICK1_000165
SPECTRUM2_001483
SPBIO_001950
PRESTWICK0_000165
SPECTRUM1502196
IDI1_000218
NCGC00093923-04
NCGC00093923-01
NCGC00015418-02
HMS2092D20
E 7138 ,
zarontin3-ethyl-3-methyl-pyrrolidine-2,5-dione
3-ethyl-3-methyl-pyrrolidine-2,5-dione(ethosuximide)
bdbm50240424
3-ethyl-3-methyl-pyrrolidine-2,5-dione (ethosuximide)
e0746 ,
NCGC00015418-06
CHEMBL696 ,
cn-10395
ethosuximidum
aethosuximide
CHEBI:4887 ,
HMS500K20
FT-0668060
HMS1568B11
HMS1921L14
AKOS005261742
HMS2095B11
HMS3261L05
unii-5seh9x1d1d
5seh9x1d1d ,
etosuccimide
5-21-09-00595 (beilstein handbook reference)
ethosuximide [usan:usp:inn:ban:jan]
pharmakon1600-01502196
nsc-758192
nsc758192
dtxcid203019
dtxsid7023019 ,
tox21_110370
S4626 ,
CCG-39217
NCGC00015418-04
NCGC00015418-05
NCGC00015418-03
NCGC00015418-08
LP00532
3-ethyl-5-hydroxy-3-methyl-3,4-dihydro-2h-pyrrol-2-one
gtpl7182
ethosuximidum [who-ip latin]
ethosuximide [usan]
ethosuximide [hsdb]
ethosuximide [mart.]
ethosuximide [vandf]
ethosuximide [usp-rs]
ethosuximide [who-dd]
ethosuximide [orange book]
ethosuximide [inn]
ethosuximide [ep monograph]
ethosuximide [usp monograph]
2,5-pyrrolidinedione, 3-ethyl-3-methyl-, (+/-)-
ethosuximide [who-ip]
ethosuximide [mi]
ethosuximide [jan]
SCHEMBL34212
tox21_110370_1
NCGC00015418-09
tox21_500532
NCGC00261217-01
CS-7976
HY-B1378
(.+/-.)-ethosuximide
.alpha.-methyl-.alpha.-ethylsuccinimide
W-109273
AB00052288_04
mfcd00072123
ethosuximide, analytical standard
4-ethyl-5-hydroxy-4-methyl-3,4-dihydro-2h-pyrrol-2-one
sr-01000075863
SR-01000075863-1
ethosuximide, united states pharmacopeia (usp) reference standard
ethosuximide, european pharmacopoeia (ep) reference standard
ethosuximide 1.0 mg/ml in methanol
SR-01000075863-5
SR-01000075863-3
SBI-0050515.P003
HMS3712B11
FT-0668061
Q421567
SCHEMBL20541518
AS-16859
BRD-A99633051-001-05-4
EN300-123801
SDCCGSBI-0050515.P004
NCGC00015418-15
HMS3885D12
D70258
Z384975088
ethosuximide (usan:usp:inn:ban:jan)
ethosuximide (usp-rs)
ethosuximide (mart.)
ethosuximidum (inn-latin)
(2rs)-2-ethyl-2-methylsuccinimide
ethosuximide (ep monograph)
ethosuximide (usp monograph)
ethosuximid
n03ad01
etosuximida (inn-spanish)

Research Excerpts

Overview

Ethosuximide (ESX) is a drug of choice for the symptomatic treatment of absence seizures. Drug-induced cognitive impairment may interfere with development, learning, and academic achievement.

ExcerptReferenceRelevance
"Ethosuximide is a difficult to retain and ionize compound in the C18 nano-flow column and ionization interface, respectively."( Microextraction combined with microderivatization for drug monitoring and protein modification analysis from limited blood volume using mass spectrometry.
Li, YS; Lu, CY; Tseng, WL; Wu, YJ, 2018
)
1.2
"Ethosuximide (ESX) is a drug of choice for the symptomatic treatment of absence seizures. "( Ethosuximide reduces epileptogenesis and behavioral comorbidity in the GAERS model of genetic generalized epilepsy.
Blumenfeld, H; Dezsi, G; Jones, NC; O'Brien, TJ; Ozturk, E; Powell, KL; Stanic, D, 2013
)
3.28
"As ethosuximide is a first-line therapy for absence seizures in childhood, and drug-induced cognitive impairment may interfere with development, learning, and academic achievement, these findings are of interest to clinicians who prescribe this drug, especially when informing parents."( The Cognitive Profile of Ethosuximide in Children.
Aldenkamp, AP; de Louw, AJ; Debeij-van Hall, MH; IJff, DM; Jansen, JF; Majoie, MH; van Veenendaal, TM, 2016
)
1.25
"Ethosuximide is a medication used to treat seizure disorders in humans, and we previously demonstrated that ethosuximide can delay age-related changes and extend the lifespan of the nematode Caenorhabditis elegans. "( The anticonvulsant ethosuximide disrupts sensory function to extend C. elegans lifespan.
Collins, JJ; Evason, K; Kornfeld, K; Pickett, CL; Schneider, DL, 2008
)
2.12
"Ethosuximide is a minor antiepileptic drug, available in France since 1965, indicated in the epilepsy absence, whose interest was reassessed from recent clinical trials, showing that it was the first choice, in term of risk benefit relationship, in this indication. "( [Therapeutic drug monitoring of ethosuximide].
Bentué-Ferrer, D; Tribut, O; Verdier, MC,
)
1.86
"Ethosuximide is a chiral drug substance primarily indicated for the treatment of absence seizures. "( Chiral aspects of the human metabolism of ethosuximide.
Galea, D; Hamilton, JT; McRoberts, WC; Mifsud, J; Millership, JS, 2005
)
2.04
"Ethosuximide is a drug used for the treatment of absence seizures. "( Neostigmine, but not metoclopramide, abolishes ethosuximide-induced functional gastrointestinal disturbances.
Kostadinova, I; Krastev, A; Sirakov, V; Turiiski, V, 2005
)
2.03
"Ethosuximide is a chiral drug substance primarily indicated for the treatment of absence seizures. "( Chiral aspects of the metabolism of ethosuximide.
Collier, PS; Hamilton, JT; McRoberts, WC; Mifsud, J; Millership, JS, 1995
)
2.01
"Ethosuximide is an antiepileptic drug successfully used in the treatment of petit mal especially in childhood. "( The ethosuximide-induced hyperpolarization of smooth muscle tissues--a cause of functional changes in the gastrointestinal tract of rats--is provoked by CA(2+)-dependent K(+)-efflux.
Kostadinova, I; Kristev, A; Lukanov, J; Sirakov, V, 1994
)
2.29
"Ethosuximide is an alternative medicament that is used for coupling of petit mal, especially in childhood. "( Ethosuximide inducted changes in the gastro-intestinal tract.
Sirakov, N; Sirakov, V; Uchikov, A; Zagorchev, P, 1998
)
3.19
"Ethosuximide is supposed to be a drug of worth to try to use in epileptic negative myoclonus patients with centrotemporal spike foci."( A case of epileptic negative myoclonus: therapeutic considerations.
Mitsuyoshi, I; Shirasaka, Y, 1999
)
1.02

Effects

ExcerptReferenceRelevance
"Ethosuximide has been associated with a wide variety of idiosyncratic reactions and with hematopoietic adverse effects."( Ethosuximide: from bench to bedside.
Gören, MZ; Onat, F, 2007
)
2.5

Actions

ExcerptReferenceRelevance
"ethosuximide, an increase after i.p."( Opposite effects of T- and L-type Ca(2+) channels blockers in generalized absence epilepsy.
Elants, C; Scheenen, W; van Luijtelaar, G; Wiaderna, D, 2000
)
1.03

Treatment

Ethosuximide in the Treatment of non-Diabetic Peripheral Neuropathic Pain (EDONOT) trial is a randomised, parallel, controlled, double-blinded, multicentre clinical study. Animals showed significant reductions in recorded spike-wave discharges (SWDs), and FST immobility time (IT) compared with untreated same age controls.

ExcerptReferenceRelevance
"The Ethosuximide in the Treatment of non-Diabetic Peripheral Neuropathic Pain (EDONOT) trial is a randomised, parallel, controlled, double-blinded, multicentre clinical study. "( Assessment of the effectiveness and safety of Ethosuximide in the Treatment of non-Diabetic Peripheral Neuropathic Pain: EDONOT-protocol of a randomised, parallel, controlled, double-blinded and multicentre clinical trial.
Chenaf, C; Duale, C; Dubray, C; Eschalier, A; Kerckhove, N; Mallet, C; Pereira, B, 2016
)
1.25
"Ethosuximide-treated animals showed significant reductions in recorded spike-wave discharges (SWDs), and FST immobility time (IT) compared with untreated same age controls. "( Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model.
Citraro, R; Constanti, A; De Fazio, S; De Sarro, G; Di Paola, ED; Perrota, I; Perrotta, I; Russo, E; Scicchitano, F, 2011
)
1.81
"Treatment with ethosuximide significantly blocks seizures in both genotypes, but the abnormal phase-amplitude coupling remains."( Persistent aberrant cortical phase-amplitude coupling following seizure treatment in absence epilepsy models.
Akbar, A; Foster, BL; Maheshwari, A; Marks, RL; Noebels, JL; Park, S; Wang, M; Yu, K, 2017
)
0.79
"Treatment with ethosuximide significantly blocks seizures in both stg/stg and tg/tg, but the abnormal PAC remains."( Persistent aberrant cortical phase-amplitude coupling following seizure treatment in absence epilepsy models.
Akbar, A; Foster, BL; Maheshwari, A; Marks, RL; Noebels, JL; Park, S; Wang, M; Yu, K, 2017
)
0.79
"Treatment with ethosuximide, an antiepileptic drug that blocks T-type calcium channels, reduces seizure activity induced by intermittent ethanol exposures and withdrawals."( Ethosuximide Reduces Mortality and Seizure Severity in Response to Pentylenetetrazole Treatment During Ethanol Withdrawal.
Godwin, DW; Masicampo, ML; Riegle, MA; Shan, HQ; Xu, V, 2015
)
2.2
"Pretreatment with ethosuximide, a drug of choice for petit mal epilepsy, was found to inhibit the conditioned avoidance response in rats and the traction response in mice and to antagonise methamphetamine induced stereotyped behaviour in rats. "( Effect of ethosuximide on dopaminergically mediated behaviours.
Balsara, JJ; Chandorkar, AG; Jadhav, JH; Jeurkar, AJ,
)
0.87

Toxicity

The acute administration of an anticonvulsant dose of ethosuximide had no effect on brain gamma-aminobutyric acid (GABA) concentration. A toxic dose (400 mg/kg) increased significantly the concentration of brain GABA (1.5%)

ExcerptReferenceRelevance
"Rare, serious adverse effects of antiepileptic drugs (AEDs) include hepatotoxicity and bone marrow suppression."( Routine laboratory monitoring for serious adverse effects of antiepileptic medications: the controversy.
Wyllie, E; Wyllie, R, 1991
)
0.28
"The acute administration of an anticonvulsant dose of ethosuximide (150 mg/kg) had no effect on brain gamma-aminobutyric acid (GABA) concentration, whereas a toxic dose (400 mg/kg) increased significantly the concentration of brain GABA (1."( Effect of ethosuximide alone and in combination with gamma-aminobutyric acid receptor agonists on brain gamma-aminobutyric acid concentration, anticonvulsant activity and neurotoxicity in mice.
Chweh, AY; Lin-Michell, E; Swinyard, EA, 1986
)
0.92
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Taking all together, this demo-case study showed that inclusion of multiple-endpoints in ZET may increase the sensitivity of the assay, contribute to the elucidation of the mode of toxic action and to a better definition of the applicability domain of ZET."( Zebrafish embryotoxicity test for developmental (neuro)toxicity: Demo case of an integrated screening approach system using anti-epileptic drugs.
Beker van Woudenberg, A; Bouma, M; de Groot, D; Hermsen, S; Menke, A; Piersma, A; Rijkmans, E; Snel, C; Wolterbeek, A, 2014
)
0.4
"The study was stopped during the interim analysis due to the high number of adverse events in the active treatment group."( Efficacy and safety of a T-type calcium channel blocker in patients with neuropathic pain: A proof-of-concept, randomized, double-blind and controlled trial.
Alchaar, H; Arcagni, P; Balp, L; Bernard, L; Bozzolo, E; Brosse, C; Creach, C; Delage, N; Delbrouck, D; Deleens, R; Duale, C; Dubray, C; Eschalier, A; Gillet, D; Gov, C; Hamdani, A; Hieng, VS; Kerckhove, N; Kuhn, E; Lambert, C; Lanteri-Minet, M; Lefebvre-Kuntz, D; Leroux-Bromberg, N; Letellier, M; Lietar, B; Lucas, C; Maindet, C; Mallet, C; Marcaillou, F; Martinez, V; Mick, G; Navez, M; Pereira, B; Perier, Y; Picard, P; Piquet, E; Richard, D; Romettino, S; Serra, E; Soriot-Thomas, S; Vergne-Salle, P, 2018
)
0.48
"Ethosuximide did not reduce the severity of neuropathic pain and induces, at the doses used, many adverse events."( Efficacy and safety of a T-type calcium channel blocker in patients with neuropathic pain: A proof-of-concept, randomized, double-blind and controlled trial.
Alchaar, H; Arcagni, P; Balp, L; Bernard, L; Bozzolo, E; Brosse, C; Creach, C; Delage, N; Delbrouck, D; Deleens, R; Duale, C; Dubray, C; Eschalier, A; Gillet, D; Gov, C; Hamdani, A; Hieng, VS; Kerckhove, N; Kuhn, E; Lambert, C; Lanteri-Minet, M; Lefebvre-Kuntz, D; Leroux-Bromberg, N; Letellier, M; Lietar, B; Lucas, C; Maindet, C; Mallet, C; Marcaillou, F; Martinez, V; Mick, G; Navez, M; Pereira, B; Perier, Y; Picard, P; Piquet, E; Richard, D; Romettino, S; Serra, E; Soriot-Thomas, S; Vergne-Salle, P, 2018
)
1.92
" The mainstay of treatment is with multiple anti-seizure medications (ASMs); however, the ASMs themselves can be associated with psychobehavioural adverse events, and effects (negative or positive) on cognition and sleep."( Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.
Schubert-Bast, S; Strzelczyk, A, 2022
)
0.72

Pharmacokinetics

The pharmacokinetic profile of ethosuximide was studied in 6 chronically catheterized male rhesus monkeys at three dose levels (30, 60, and 90 mg/kg), intravenously and orally. Hemodialysis reduced the elimination half-life of ethosUXimide from a presumable value of 55 hours to an average of 3.

ExcerptReferenceRelevance
"MULTDOS, a computer method to curve fit data obtained on multiple dosing, was used with either the 1969 or 1974 version of the NONLIN program to compare the pharmacokinetic parameters of ethosuximide during repetitive administration of single or divided daily doses."( Use of MULTDOS for pharmacokinetic analysis of ethosuximide data during repetitive administration of single or divided daily doses.
Colburn, WA; Gibaldi, M, 1978
)
0.71
" Comparison of the pharmacokinetic data for dog and man reveals, in spite of the somewhat shorter half-life in the dog, a rather good agreement."( Pharmacokinetics of ethosuximide in the dog.
el Sayed, MA; Frey, HH; Löscher, W, 1978
)
0.58
"Anticonvulsant therapy was among the first areas to benefit from clinical pharmacokinetic studies."( Clinical pharmacokinetics of anticonvulsants.
Dam, M; Hvidberg, EF, 1976
)
0.26
"The pharmacokinetic profile of ethosuximide was studied in 6 chronically catheterized male rhesus monkeys at three dose levels (30, 60, and 90 mg/kg), intravenously and orally."( Pharmacokinetic properties of ethosuximide in monkeys. I. Single-dose intravenous and oral administration.
Bauer, TG; Levy, RH; Patel, IH, 1975
)
0.83
" Zero-order infusion rates and priming and maintenance doses were calculated for each animal using individual single-dose pharmacokinetic parameters."( Pharmacokinetic properties of ethosuximide in monkeys. II. Chronic intravenous and oral administration.
Levy, RH; Patel, IH, 1975
)
0.54
" Pharmacokinetic interactions between antiepileptic drugs may lead to considerable fluctuation in plasma drug concentration, and monotherapy is often preferable."( Pharmacokinetics of antiepileptic drugs.
Neuvonen, PJ; Tokola, RA, 1983
)
0.27
"The present pharmacokinetic study was designed to investigate the possible interaction between valproic acid (VPA) and ethosuximide (ESM) in humans."( Valproic acid-ethosuximide interaction: a pharmacokinetic study.
Di Perri, R; Fazio, A; La Rosa, G; Narbone, MC; Oteri, G; Pisani, F; Trunfio, C, 1984
)
0.84
" This review contains relevant pharmacokinetic data on anticonvulsant drugs widely used during pregnancy and the neonatal period."( Anticonvulsants during pregnancy and lactation. Transplacental, maternal and neonatal pharmacokinetics.
Egger, HJ; Helge, H; Kuhnz, W; Nau, H; Rating, D,
)
0.13
" Particular attention has been paid to the role of age in determining the variability of pharmacokinetic parameters, but the effect of other factors, such as different formulations and routes of administration, concomitant treatments, gender and pathological conditions other than epilepsy, have also been considered."( Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.
Avanzini, G; Battino, D; Estienne, M, 1995
)
0.5
" The median elimination half-life (t1/2) in patients receiving concomitant valproate (VPA) was 43."( Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy.
Boreus, L; Eriksson, AS; Hoppu, K; Nergårdh, A, 1996
)
0.29
" Clearance, volume of distribution, and elimination half-life were scaled up from animal data obtained from literature."( Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance.
Balian, JD; Mahmood, I, 1996
)
0.29
" Pharmacokinetic parameters were estimated using standard non-compartmental methods."( The pharmacokinetics of ethosuximide enantiomers in the rat.
Collier, PS; Mifsud, J; Millership, JS, 2001
)
0.62
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005
)
0.33
" Any pharmacokinetic contribution was ascertained by measurement of brain antiepileptic drug (AED) concentrations."( Pharmacodynamic and/or pharmacokinetic characteristics of interactions between loreclezole and four conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic analysis.
Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2005
)
0.33
" Brain AED concentrations were also measured so as to ascertain any pharmacokinetic contribution to the pharmacodynamic interactions."( Characterization of the anticonvulsant, behavioral and pharmacokinetic interaction profiles of stiripentol in combination with clonazepam, ethosuximide, phenobarbital, and valproate using isobolographic analysis.
Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2006
)
0.54
" However, these interactions were complicated by changes in brain AED concentrations consequent to pharmacokinetic interactions."( Characterization of the anticonvulsant, behavioral and pharmacokinetic interaction profiles of stiripentol in combination with clonazepam, ethosuximide, phenobarbital, and valproate using isobolographic analysis.
Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2006
)
0.54
" However, these conclusions are confounded by the fact that STP is associated with significant pharmacokinetic interactions."( Characterization of the anticonvulsant, behavioral and pharmacokinetic interaction profiles of stiripentol in combination with clonazepam, ethosuximide, phenobarbital, and valproate using isobolographic analysis.
Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2006
)
0.54
" Corresponding plasma pharmacokinetic profiles of ethosuximide were compared, along with palatability, safety, and tolerability."( An innovative ethosuximide granule formulation designed for pediatric use: Comparative pharmacokinetics, safety, tolerability, and palatability profile versus reference syrup.
André, P; Bardinet, C; Brunner-Ferber, F; Buclin, T; Burton, I; Chiron, C; Chtioui, H; Dao, K; Diezi, L; Granier, LA; Guittet, C; Jullien, V; Manso-Silvan, MA; Rothuizen, LE; Roussel-Maupetit, C; Vandenhende, F, 2023
)
1.52

Compound-Compound Interactions

ExcerptReferenceRelevance
"Valproic acid undergoes drug-drug interactions with most of the commonly used anticonvulsants."( Drug interactions with valproic acid.
Koch, KM; Levy, RH, 1982
)
0.26
" Because of its widespread and long term use, carbamazepine is frequently prescribed in combination with other drugs, leading to the possibility of drug interactions."( Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.
Perucca, E; Pisani, F; Spina, E, 1996
)
0.29
"The anticonvulsant and acute adverse (neurotoxic) effects of STP in combination with the various conventional antiepileptic drugs (AEDs), at fixed ratios of 1:3, 1:1, and 3:1, were evaluated in the PTZ and chimney tests in mice using the isobolographic analysis."( Characterization of the anticonvulsant, behavioral and pharmacokinetic interaction profiles of stiripentol in combination with clonazepam, ethosuximide, phenobarbital, and valproate using isobolographic analysis.
Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2006
)
0.54
" Adverse-effect profiles of the drugs in combination were determined and brain AED concentrations were measured."( Isobolographic characterization of the anticonvulsant interaction profiles of levetiracetam in combination with clonazepam, ethosuximide, phenobarbital and valproate in the mouse pentylenetetrazole-induced seizure model.
Andres-Mach, MM; Czuczwar, SJ; Dudra-Jastrzebska, M; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2009
)
0.56

Bioavailability

ExcerptReferenceRelevance
" They appear to be well absorbed when given by mouth, but their patterns of distribution within the body are different."( Pharmacokinetics of drugs used for petit mal 'absence' epilepsy.
Eadie, MJ; McKauge, L; Smith, GA; Tyrer, JH, 1977
)
0.26
" The absorption rate and fraction are very much dependent on the pharmaceutical preparation, and changes of brand may alter the plasma level of phenytoin in spite of unaltered dose."( Clinical pharmacokinetics of anticonvulsants.
Dam, M; Hvidberg, EF, 1976
)
0.26
" Carbamazepine is well absorbed and largely metabolized."( Pharmacokinetics of antiepileptic drugs.
Neuvonen, PJ; Tokola, RA, 1983
)
0.27
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" Compound 30 showed good oral bioavailability and brain penetration across species."( Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.
Adarayan, ED; Ballard, JE; Barrow, JC; Bock, MG; Bunting, PB; Connolly, TM; DiLella, AG; Doran, SM; Fox, SV; Graufelds, VK; Hartman, GD; Koblan, KS; Kraus, RL; Kuo, Y; Lindsley, CW; Magee, MM; Marino, MJ; Nuss, CE; Prueksaritanont, T; Renger, JJ; Reynolds, IJ; Rittle, KE; Schlegel, KA; Shipe, WD; Shu, Y; Tang, C; Uebele, VN; Vargas, HM; Woltmann, RF; Yang, FV; Yang, ZQ; Zrada, MM, 2008
)
0.35
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

VPA was found to be an effective anticonvulsant agent. ethosuximide and diazepam were ineffective at dosage levels that are normally effective in mice as determined by classical testing methods such as electroshock and chemoshock. Hemodialysis patients concurrently receiving VPA may require a supplemental dose or an altered ethosuxinide dosing schedule.

ExcerptRelevanceReference
"Gamma hydroxybutyrate (GHB) was administered intravenously to monkeys that had been pretreated orally for 2 weeks with various anticonvulsant drugs or with L-DOPA at different dosage levels."( Gamma hydroxybutyrate in the monkey. II. Effect of chronic oral anticonvulsant drugs.
Snead, OC, 1978
)
0.26
" The 3 drugs also show differences in elimination rate, which make it desirable to give valproate 3 times a day and clonazepam twice a day, whereas ethosuximide could reasonably be given once daily without undesirably wide fluctuations in plasma drug level over the dosage interval."( Pharmacokinetics of drugs used for petit mal 'absence' epilepsy.
Eadie, MJ; McKauge, L; Smith, GA; Tyrer, JH, 1977
)
0.46
" It is useful alone or as an adjunct to other anticonvulsants and may allow the dosage of the latter to be reduced."( Valproic acid (Depakene). A new anticonvulsant agent.
Lewis, JR, 1978
)
0.26
" Elimination rate constants, excretion rate constants, and apparent volumes of distribution were similar between the two dosing regimens and essentially identical between the two nonlinear regression programs."( Use of MULTDOS for pharmacokinetic analysis of ethosuximide data during repetitive administration of single or divided daily doses.
Colburn, WA; Gibaldi, M, 1978
)
0.52
" Combined treatment with other anticonvulsant drugs decreases the half-life and more frequent dosing may be necessary."( Clinical pharmacokinetics of anticonvulsants.
Dam, M; Hvidberg, EF, 1976
)
0.26
" Three had grand mal seizures but the frequency did not differ between the dosage regimens."( Ethosuximide dosage regimens.
Buchanan, RA; Heffelfinger, JC; Kinkel, AW; Turner, JL, 1976
)
1.7
"17 hr following intravenous and oral administration, respectively) remained constant over the dosage range Appendix) was selected to describe the disposition of ethosuximide in monkeys."( Pharmacokinetic properties of ethosuximide in monkeys. I. Single-dose intravenous and oral administration.
Bauer, TG; Levy, RH; Patel, IH, 1975
)
0.74
"Three types of chronic-dosing experiments were implemented in a group of chronically catheterized male rhesus monkeys: Study I, constant rate infusion; Study II, infusion at three consecutive rates with priming doses; and Study III, oral multiple dosing at two consecutive levels with priming doses."( Pharmacokinetic properties of ethosuximide in monkeys. II. Chronic intravenous and oral administration.
Levy, RH; Patel, IH, 1975
)
0.54
"Pigeons were trained in a cumulative dosing procedure to emit one response in the presence of 15 mg/kg phenytoin and another response in the absence of phenytoin."( Discriminative stimulus properties of phenytoin in the pigeon: determination via a cumulative dosing procedure.
Clark, R; Poling, A; Schlinger, H, 1990
)
0.28
" The technique is simple and rapid: 4 anticonvulsants are simultaneously extracted and dosed, valproic acid, only has to be dosed lonely."( [Plasma determination of 7 common drugs by high performance liquid chromatography].
Baty, C; Jambou, J; Leducq, B; Richard, L, 1989
)
0.28
" In response to the effects of enzyme induction, valproate dosage may need to be doubled to maintain therapeutic serum levels."( Pharmacologic interactions between valproate and other drugs.
Bourgeois, BF, 1988
)
0.27
" Dose-response curves for the convulsive effect of pentylenetetrazol obtained at the peak of the withdrawal signs shifted greatly to the left in alcohol withdrawn animals but less in barbital withdrawn animals."( Differentiation of alcohol and barbital physical dependence.
Kaneda, H; Kaneto, H; Kawatani, S, 1986
)
0.27
" The relation between the ethosuximide dosage given and the plasma concentration level was good."( Evaluation of treatment in typical absence seizures. The roles of long-term EEG monitoring and ethosuximide.
Blomquist, HK; Zetterlund, B, 1985
)
0.79
" Acute intraperitoneal administration of the other drugs revealed VPA to be an effective anticonvulsant agent, whereas ethosuximide and diazepam were ineffective at dosage levels that are normally effective in mice as determined by classical testing methods such as electroshock and chemoshock."( Seizure control following administration of anticonvulsant drugs in the quaking mouse.
Abbott, LC; Bennett, GD; Finnell, RH; Taylor, SM, 1985
)
0.48
" The dose-response curve of the effects has a shape similar to that for ethanol."( Excitable channel currents and gating times in the presence of anticonvulsants ethosuximide and valproate.
Adelman, WJ; Brennan, JJ; Fohlmeister, JF, 1984
)
0.5
" The dose-response curve for naloxone against seizure activity induced by leucine enkephalin was the same as that in gamma-hydroxybutyrate-induced petit mal."( Anticonvulsants specific for petit mal antagonize epileptogenic effect of leucine enkephalin.
Bearden, LJ; Snead, OC, 1980
)
0.26
" The results show that all three of these anticonvulsants depress postjunctional sensitivity to released acetylcholine producing parallel dose-response curves for MEPP amplitude inhibition."( Differential effects of the anticonvulsants phenobarbital, ethosuximide and carbamazepine on neuromuscular transmission.
Alderdice, MT; Trommer, BA, 1980
)
0.5
" In contrast, cannabidiol, over a wide dosage range, caused only depression."( Excitatory and depressant effects of delta 9-tetrahydrocannabinol and cannabidiol on cortical evoked responses in the conscious rat.
Karler, R; Turkanis, SA, 1981
)
0.26
" Active compounds exhibited an inverted U-shaped dose-response curve."( Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
Butler, DE; L'Italien, YJ; Marriott, JG; Nordin, IC; Poschel, PH; Zweisler, L, 1984
)
0.27
" Fortunately, the drugs used by the majority of these patients are readily measured in plasma, and in most cases the plasma concentration is a valid measure of the appropriateness of the dosage of drug administered."( Antiepileptic therapeutic drug monitoring.
Cohan, SL, 1981
)
0.26
" However, displacement alone, unlike induced metabolism, should not affect the drug's dose-response relationship."( Drug interactions with valproic acid.
Koch, KM; Levy, RH, 1982
)
0.26
" All active compounds gave inverted U-shaped dose-response curves."( Cognition-activating properties of 3-(Aryloxy)pyridines.
Butler, DE; Marriott, JG; Poschel, BP, 1981
)
0.26
" Hemodialysis patients concurrently receiving ethosuximide may require a supplemental dose or an altered ethosuximide dosing schedule."( Hemodialysis clearance of ethosuximide in patients with chronic renal disease.
Lee, CS; Marbury, TC; Perchalski, RJ; Wilder, BJ, 1981
)
0.82
" In order to test the validity of FEAD as an absence seizure model, the present experiments determined dose-response relationships for the suppression of FEAD by six antiepileptic drugs with established clinical profiles."( Flash-evoked afterdischarge in rat as a model of the absence seizure: dose-response studies with therapeutic drugs.
Burnham, WM; King, GA; Livingston, KE, 1980
)
0.26
" For 12 patients, treatment could be reduced to monotherapy, but for those with valproate (VPA) comedication LTG dosage had to be increased; 25% of patients with VPA monotherapy exhibited skin rash, appearing 3-18 days after starting LTG."( Lamotrigine in treatment of 120 children with epilepsy.
Chavez, F; Dulac, O; Pajot, N; Palacios, L; Rey, E; Schlumberger, E,
)
0.13
" Hill slope coefficients for the tested anticonvulsants indicate that the dose-response curve was less steep for gabapentin than for phenytoin, carbamazepine and ethosuximide."( Potent analgesic effects of anticonvulsants on peripheral thermal nociception in rats.
Jevtovic-Todorovic, V; Rastogi, AJ; Todorovic, SM, 2003
)
0.52
" Repetitive dosing with ethosuximide (i."( Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy.
Bennett, GJ; Flatters, SJ, 2004
)
2.07
" In mice given high drug dosing (100 mg/kg), seminiferous tubules showed immaturity with spermatogenic arrest at elongating spermatid stage and poorly developed lumen."( Effects of calcium channel blockers on the spermatogenesis and gene expression in peripubertal mouse testis.
Gye, MC; Kim, DH; Kim, H; Lee, JH,
)
0.13
" However, dose-response studies showed that lower doses of CGP35348 that failed to influence atypical absence seizure activity, completely reversed the spatial working memory deficit."( GABAB receptor antagonism abolishes the learning impairments in rats with chronic atypical absence seizures.
Burnham, WM; Chan, KF; Cortez, MA; Jia, Z; Snead, OC, 2006
)
0.33
" The results indicated that both drugs produced clear anticonvulsant effects against PTZ-induced clonic seizures in mice, but that their dose-response relationship curves (DRRCs) were not parallel, consequently necessitating the isobolographic analysis for non-parallel DRRCs."( Interactions of tiagabine with ethosuximide in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis for non-parallel dose-response relationship curves.
Luszczki, JJ, 2008
)
0.63
" Moreover, the flexible chip may offer advantages over conventional drug delivery devices by improvement of dosing precision, ease of operation, wider versatility of elution pattern, and better compliance."( A flexible drug delivery chip for the magnetically-controlled release of anti-epileptic drugs.
Chen, SY; Hu, SH; Huang, WC; Liu, DM; Liu, KH, 2009
)
0.35
"The aim of this review was to evaluate current literature for dosing recommendations for the use of antiepileptic medications in patients receiving renal replacement therapy (RRT)."( Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy.
Bastin, ML; Cook, AM; Oyler, DR; Smetana, KS, 2016
)
0.43
" Micromedex® DRUGDEX as well as package inserts were used to obtain known pharmacokinetic properties and dosage adjustment recommendations in RRT if known."( Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy.
Bastin, ML; Cook, AM; Oyler, DR; Smetana, KS, 2016
)
0.43
"Data regarding antiepileptic drug use in RRT are limited and mostly consist of case reports limiting our proposed dosing recommendations."( Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy.
Bastin, ML; Cook, AM; Oyler, DR; Smetana, KS, 2016
)
0.43
"Additional studies are necessary before specific dosing recommendations can be made for most antiepileptic drugs in critically ill patients receiving RRT, specifically with newer agents."( Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy.
Bastin, ML; Cook, AM; Oyler, DR; Smetana, KS, 2016
)
0.43
" We diagnosed both patients with ethosuximide-induced SJS, based on the dosing period and the positive results of drug-induced lymphocyte stimulation test."( Ethosuximide-induced Stevens-Johnson syndrome: Beneficial effect of early intervention with high-dose corticosteroid therapy.
Fujii, K; Hamada, T; Iwatsuki, K; Kobayashi, K; Shibata, T; Tachibana, K; Tsuchiya, H, 2018
)
2.2
" This study aimed to characterize the initial monotherapy ethosuximide exposure-response relationship and to propose model-informed precision dosing guidance."( Model-Informed Precision Dosing Guidance of Ethosuximide Developed from a Randomized Controlled Clinical Trial of Childhood Absence Epilepsy.
Adamson, PC; Blumer, JL; Capparelli, EV; Clark, PO; Cnaan, A; Dong, M; Fukuda, T; Glauser, TA; Mizuno, K; Reed, MD; Shinnar, S; Vinks, AA, 2023
)
1.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
anticonvulsantA drug used to prevent seizures or reduce their severity.
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
T-type calcium channel blockerAny agent that interferes with the activity of T-type calcium channels.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
pyrrolidinone
dicarboximideAn imide in which the two acyl substituents on nitrogen are carboacyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency43.64860.002541.796015,848.9004AID1347398
thioredoxin reductaseRattus norvegicus (Norway rat)Potency29.93490.100020.879379.4328AID588453
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency0.95213.189029.884159.4836AID1224846
GLS proteinHomo sapiens (human)Potency5.62340.35487.935539.8107AID624146
AR proteinHomo sapiens (human)Potency21.13170.000221.22318,912.5098AID743042
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency5.30800.000657.913322,387.1992AID1259377
EWS/FLI fusion proteinHomo sapiens (human)Potency28.32920.001310.157742.8575AID1259253; AID1259256
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency20.49470.001530.607315,848.9004AID1224820; AID1224841
arylsulfatase AHomo sapiens (human)Potency8.91251.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.00600.035520.977089.1251AID504332
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency2.81840.00798.23321,122.0200AID2551
neuropeptide S receptor isoform AHomo sapiens (human)Potency25.11890.015812.3113615.5000AID1461
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)566.50000.11007.190310.0000AID1449628; AID1473738
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Voltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)IC50 (µMol)5,000.00000.08600.65472.5000AID390816
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (45)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
signal transductionVoltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)
neuronal action potentialVoltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)
sleepVoltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (26)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)
protein bindingVoltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (18)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
plasma membraneVoltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (642)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID489282Anticonvulsant activity against subcutaneous pentylenetetrazole-induced seizures in ip dosed Swiss albino mouse assessed as minimum effective dose after 4 hrs2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Novel semicarbazones based 2,5-disubstituted-1,3,4-oxadiazoles: one more step towards establishing four binding site pharmacophoric model hypothesis for anticonvulsant activity.
AID131586Subcutaneous metrazole (scMet) test was conducted and median effective dose was determined at the time of peak anticonvulsant and sedative effect.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and anticonvulsant activity of some new 2-substituted 3-aryl-4(3H)-quinazolinones.
AID666665Anticonvulsant activity in Kunming mouse assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip measured after 0.5 hr2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and anticonvulsant activity of ethyl 1-(2-arylhydrazinecarboxamido)-2,2-dimethylcyclopropanecarboxylate derivatives.
AID623179Neurotoxicity in CF1 albino mouse assessed as impair in motor coordination at 300 mg/kg, ip after 0.5 hrs by rotarod test2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Synthesis and anticonvulsant activity of new N-Mannich bases derived from 5-cyclopropyl-5-phenyl- and 5-cyclopropyl-5-(4-chlorophenyl)-imidazolidine-2,4-diones.
AID231428Protective index was calculated (TD50/ED50) in scMET assay in rat after oral administration1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Synthesis and anticonvulsant activity of 2-benzylglutarimides.
AID221082Therapeutic dosage was measured by ip administration in mice; 383-4851993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis and CLOGP correlation of imidooxy anticonvulsants.
AID621011Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures after 4 hrs2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Synthesis and anticonvulsant activity of new 1-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]pyrrolidine-2,5-diones.
AID230048Ratio of LD50/HD50 was determined1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Synthesis and anticonvulsant activity of 2-benzylglutarimides.
AID727987Antiepileptic activity in Swiss albino mouse assessed as protection against maximal-electric shock-induced seizures at 300 mg/kg, ip measured after 0.5 hrs2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Novel limonene and citral based 2,5-disubstituted-1,3,4-oxadiazoles: a natural product coupled approach to semicarbazones for antiepileptic activity.
AID626753Anticonvulsant activity in po dosed Sprague-Dawley rat assessed as time needs to show peak effect for protection against subcutaneous metrazol-induced seizure after 0.25 hrs2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and anticonvulsant activity of novel 2,6-diketopiperazine derivatives. Part 1: perhydropyrrole[1,2-a]pyrazines.
AID1264984Neurotoxicity in Swiss albino mouse assessed as inability of animal to maintain equilibrium on rod at 300 mg/kg, ip after 0.5 hrs by rotarod test2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis of 2,6-dicarbethoxy-3,5-diaryltetrahydro-1,4-thiazine-1,1-dioxide derivatives as potent anticonvulsant agents.
AID226511Protective Index (PI) determined as the ratio of toxic dose (TD50) and effective dose (ED50 (MES))1997Journal of medicinal chemistry, Jan-03, Volume: 40, Issue:1
Synthesis and anticonvulsant activities of 3,3-dialkyl- and 3-alkyl-3-benzyl-2-piperidinones (delta-valerolactams) and hexahydro-2H-azepin-2-ones (epsilon-caprolactams).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID286838Anticonvulsant activity in Swiss Albino mouse at 300 mg/kg, ip after 0.5 hr by MES test2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Discovery of 4-aminobutyric acid derivatives possessing anticonvulsant and antinociceptive activities: a hybrid pharmacophore approach.
AID118791Compound was tested for cognitive activity by measuring retention for passive avoidance learning in mice at dose 20 mg/kg i1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Cognition-activating properties of 3-(Aryloxy)pyridines.
AID516038Anticonvulsant activity in Sprague-Dawley rat assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 50 mg/kg po after 0.5 hrs2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Design, synthesis, and anticonvulsant activity of new N-Mannich bases derived from spirosuccinimides and spirohydantoins.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID623096Neurotoxicity in Sprague-Dawley albino rat assessed as motor impairment at 50 mg/kg, po after 0.25 hrs by rotarod test2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Synthesis and anticonvulsant activity of new N-Mannich bases derived from 5-cyclopropyl-5-phenyl- and 5-cyclopropyl-5-(4-chlorophenyl)-imidazolidine-2,4-diones.
AID779005Neurotoxicity in po dosed albino Sprague-Dawley rat assessed as time to peak effect by rotorod test2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Design, synthesis and anticonvulsant properties of new N-Mannich bases derived from 3-phenylpyrrolidine-2,5-diones.
AID396415Anticonvulsant activity in Swiss albino mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 300 mg/kg, ip administered 30 mins before PTZ challenge measured after 4 hrs post PTZ challenge2008European journal of medicinal chemistry, Dec, Volume: 43, Issue:12
Newer GABA derivatives for the treatment of epilepsy including febrile seizures: a bioisosteric approach.
AID626854Anticonvulsant activity in ip dosed albino Carworth Farms No.1 mouse assessed as time needs to show peak effect for protection against subcutaneous metrazol-induced seizure2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and anticonvulsant activity of novel 2,6-diketopiperazine derivatives. Part 1: perhydropyrrole[1,2-a]pyrazines.
AID516039Anticonvulsant activity in Sprague-Dawley rat assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 50 mg/kg po after 1 hr2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Design, synthesis, and anticonvulsant activity of new N-Mannich bases derived from spirosuccinimides and spirohydantoins.
AID477741Neurotoxicity in Swiss albino mouse at 300 mg/kg, ip after 4 hrs2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening.
AID29360Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID767983Induction of mutagenecity in Vibrio harveyi BB7X2013European journal of medicinal chemistry, Aug, Volume: 66Synthesis and biological properties of new N-Mannich bases derived from 3-methyl-3-phenyl- and 3,3-dimethyl-succinimides. Part V.
AID516040Anticonvulsant activity in Sprague-Dawley rat assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 50 mg/kg po after 2 hrs2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Design, synthesis, and anticonvulsant activity of new N-Mannich bases derived from spirosuccinimides and spirohydantoins.
AID113977Anticonvulsant activity was determined by subcutaneous Metrazol-induced convulsions seizure test (Phase II Pharmacological Evaluation)1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Functionalized DL-amino acid derivatives. Potent new agents for the treatment of epilepsy.
AID132470The compound was tested for anticonvulsant activity against (subcutaneous administered) Metrazol induced seizures after intraperitoneal administration1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Synthesis and anticonvulsant activity of 2-benzylglutarimides.
AID1246365Anticonvulsant activity in ip dosed albino CD-1 mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizure measured as time to peak effect2015European journal of medicinal chemistry, Sep-18, Volume: 102Design, synthesis and biological activity of new amides derived from 3-methyl-3-phenyl-2,5-dioxo-pyrrolidin-1-yl-acetic acid.
AID287115Anticonvulsant activity in Albino CF1 mouse upto 300 mg/kg, ip in maximal electroshock seizure test2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
Design and synthesis of anticonvulsants from a combined phthalimide-GABA-anilide and hydrazone pharmacophore.
AID629162Neurotoxicity in Swiss albino mouse assessed as minimal motor impairment at 300 mg/kg, ip after 0.5 hrs by rotarod test2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Design, synthesis and antiepileptic properties of novel 1-(substituted benzylidene)-3-(1-(morpholino/piperidino methyl)-2,3-dioxoindolin-5-yl)urea derivatives.
AID1065326Anticonvulsant activity in po dosed albino rat assessed as protection against maximal electroshock-induced seizures after 2 hrs2013European journal of medicinal chemistry, Sep, Volume: 67Design, synthesis and anticonvulsant evaluation of N-(benzo[d]thiazol-2-ylcarbamoyl)-2-methyl-4-oxoquinazoline-3(4H)-carbothioamide derivatives: a hybrid pharmacophore approach.
AID1246355Anticonvulsant activity in albino CD-1 mouse assessed as protection against maximal electroshock-induced seizure at 30 to 300 mg/kg, ip measured after 0.5 hrs2015European journal of medicinal chemistry, Sep-18, Volume: 102Design, synthesis and biological activity of new amides derived from 3-methyl-3-phenyl-2,5-dioxo-pyrrolidin-1-yl-acetic acid.
AID1415361Anticonvulsant activity in mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 50 mg/kg, ip measured for 30 mins post pentylenetetrazole challenge at 0.5 hrs after compound dosing relative to control2017MedChemComm, Jan-01, Volume: 8, Issue:1
Design, synthesis and anticonvulsant-analgesic activity of new
AID1183252Protective index, ratio of TD50 for neurotoxicity in po dosed albino Wistar rat to ED50 for anticonvulsant activity in po dosed albino Wistar rat assessed as protection against subcutaneous pentylenetetrazol-induced seizures at 2 hrs2014European journal of medicinal chemistry, Sep-12, Volume: 84Design and synthesis of new of 3-(benzo[d]isoxazol-3-yl)-1-substituted pyrrolidine-2, 5-dione derivatives as anticonvulsants.
AID1143179Anticonvulsant activity in ip dosed Swiss albino mouse assessed as protection against maximal electroshock-induced seizure measured at the time of peak effect during phase 2 trials by MES test2014European journal of medicinal chemistry, Jun-10, Volume: 80Anticonvulsant evaluation of clubbed indole-1,2,4-triazine derivatives: a synthetic approach.
AID168747Median Effective dose was evaluated by Maximal electroshock seizure (MES) test in Rats by oral administration up to 1200 mg/kg; g= no protection1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Synthesis and evaluation of N-(phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents.
AID623227Anticonvulsant activity in ip dosed CF1 albino mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures after 0.5 hrs2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Synthesis and anticonvulsant activity of new N-Mannich bases derived from 5-cyclopropyl-5-phenyl- and 5-cyclopropyl-5-(4-chlorophenyl)-imidazolidine-2,4-diones.
AID1143161Anticonvulsant activity in Swiss albino mouse assessed as protection against maximal electroshock-induced tonic-clonic seizure spread measured at 300 mg/kg, ip after 0.5 hrs by MES test2014European journal of medicinal chemistry, Jun-10, Volume: 80Anticonvulsant evaluation of clubbed indole-1,2,4-triazine derivatives: a synthetic approach.
AID666673Neurotoxicity in Kunming mouse at 300 mg/kg, ip after 0.5 hr by rotorod test2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and anticonvulsant activity of ethyl 1-(2-arylhydrazinecarboxamido)-2,2-dimethylcyclopropanecarboxylate derivatives.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1246368Protective index, ratio of TD50 for neurotoxicity in ip dosed albino CD-1 mouse to ED50 for anticonvulsant activity in ip dosed subcutaneous pentylenetetrazole-induced seizure albino CD-1 mouse model2015European journal of medicinal chemistry, Sep-18, Volume: 102Design, synthesis and biological activity of new amides derived from 3-methyl-3-phenyl-2,5-dioxo-pyrrolidin-1-yl-acetic acid.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1720865Protective index, ratio of TD50 for neurotoxicity in ip injected albino mouse to ED50 for anticonvulsant activity in albino mouse assessed as pentylenetetrazole-induced seizure2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants.
AID516026Neurotoxicity in CF1 albino mouse at 300 mg/kg, ip after 4 hrs by rotarod test2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Design, synthesis, and anticonvulsant activity of new N-Mannich bases derived from spirosuccinimides and spirohydantoins.
AID1065325Neurotoxicity in po dosed albino rat after 2 hrs2013European journal of medicinal chemistry, Sep, Volume: 67Design, synthesis and anticonvulsant evaluation of N-(benzo[d]thiazol-2-ylcarbamoyl)-2-methyl-4-oxoquinazoline-3(4H)-carbothioamide derivatives: a hybrid pharmacophore approach.
AID1246359Neurotoxicity in albino CD-1 mouse assessed as motor impairment at 30 to 300 mg/kg mg/kg, ip measured after 0.5 hrs by rotarod test2015European journal of medicinal chemistry, Sep-18, Volume: 102Design, synthesis and biological activity of new amides derived from 3-methyl-3-phenyl-2,5-dioxo-pyrrolidin-1-yl-acetic acid.
AID132474Anticonvulsant activity against subcutaneous picrotoxin induced seizures after intraperitoneal administration1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Synthesis and anticonvulsant activity of 2-benzylglutarimides.
AID1863979Anti-seizure activity against electrical stimulus induced seizure in ip dosed CD-1 mouse model assessed as normal behavior within 10 seconds after stimulation at 6 Hz and 32 mA for 3 secs pretreated for 0.25 hr by psychomotor seizure test
AID683941Anticonvulsant activity in CF-1 albino mouse assessed as protection from maximal electric shock-induced seizures at 300 mg/kg, ip measured after 0.5 hrs2012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Synthesis and anticonvulsant activity of new N-Mannich bases derived from 3-(2-fluorophenyl)- and 3-(2-bromophenyl)-pyrrolidine-2,5-diones. Part II.
AID780685Anticonvulsant activity in ip dosed albino mouse assessed as protection against 6 Hz psychomotor seizure by minimal clonic seizure test2013Bioorganic & medicinal chemistry letters, Nov-15, Volume: 23, Issue:22
Structure-activity relationships of the aromatic site in novel anticonvulsant pyrrolo[1,2-a]pyrazine derivatives.
AID666672Anticonvulsant activity in Kunming mouse assessed as protection against subcutaneous pentylenetetrazol-induced clonic seizures at 300 mg/kg, ip measured after 4 hrs2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and anticonvulsant activity of ethyl 1-(2-arylhydrazinecarboxamido)-2,2-dimethylcyclopropanecarboxylate derivatives.
AID623093Neurotoxicity in Sprague-Dawley albino rat assessed as motor impairment at 50 mg/kg, po after 2 hrs by rotarod test2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Synthesis and anticonvulsant activity of new N-Mannich bases derived from 5-cyclopropyl-5-phenyl- and 5-cyclopropyl-5-(4-chlorophenyl)-imidazolidine-2,4-diones.
AID1576060Neurotoxicity in ip dosed mouse assessed as maximum tolerated dose by rotarod test2019MedChemComm, Aug-01, Volume: 10, Issue:8
Derivatives of a new heterocyclic system - pyrano[3,4-
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID727986Antiepileptic activity in Swiss albino mouse assessed as protection against maximal-electric shock-induced seizures at 300 mg/kg, ip measured after 4 hrs2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Novel limonene and citral based 2,5-disubstituted-1,3,4-oxadiazoles: a natural product coupled approach to semicarbazones for antiepileptic activity.
AID286854Neurotoxicity in Swiss Albino mouse at 300 mg/kg, ip after 0.5 hr by rotarod test2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Discovery of 4-aminobutyric acid derivatives possessing anticonvulsant and antinociceptive activities: a hybrid pharmacophore approach.
AID1143180Neurotoxicity in ip dosed Swiss albino mouse measured during phase 2 trials by rotarod test2014European journal of medicinal chemistry, Jun-10, Volume: 80Anticonvulsant evaluation of clubbed indole-1,2,4-triazine derivatives: a synthetic approach.
AID1161075Protective index, ratio of TD50 for neurotoxicity in ip dosed albino CF1 mouse to ED50 for anticonvulsant activity in ip dosed 6 Hz current-induced seizure albino CF1 mouse model2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Novel fluorinated pyrrolo[1,2-a]pyrazine-2,6-dione derivatives: synthesis and anticonvulsant evaluation in animal models of epilepsy.
AID1432534Neurotoxicity in ip dosed albino CD1 mouse assessed as motor impairment by rotarod test2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Synthesis and evaluation of anticonvulsant properties of new N-Mannich bases derived from pyrrolidine-2,5-dione and its 3-methyl-, 3-isopropyl, and 3-benzhydryl analogs.
AID1264977Anticonvulsant activity in Swiss albino mouse assessed as reduction of maximal electroshock-induced seizure at 300 mg/kg, ip after 4 hrs2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis of 2,6-dicarbethoxy-3,5-diaryltetrahydro-1,4-thiazine-1,1-dioxide derivatives as potent anticonvulsant agents.
AID131996Median hypnotic dose by loss of righting reflex.1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Synthesis and anticonvulsant activity of 2-benzylglutarimides.
AID136258Neurological deficit in mouse measured by rotarod test1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Triazolines. 14. 1,2,3-Triazolines and triazoles, a new class of anticonvulsants. Drug design and structure-activity relationships.
AID113699Inhibition of seizures induced in mice by a convulsant dose of bicuculline through ip administration1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Synthesis and evaluation of N-(phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents.
AID1183226Anticonvulsant activity in ip dosed albino Swiss mouse assessed as assessed as protection against subcutaneous pentylenetetrazol-induced seizures at 4 hrs2014European journal of medicinal chemistry, Sep-12, Volume: 84Design and synthesis of new of 3-(benzo[d]isoxazol-3-yl)-1-substituted pyrrolidine-2, 5-dione derivatives as anticonvulsants.
AID628631Anticonvulsant activity in CF1 albino mouse assessed as protection against maximal electroshock at 300 mg/kg, ip after 4 hrs2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and anticonvulsant properties of new acetamide derivatives of phthalimide, and its saturated cyclohexane and norbornene analogs.
AID1173473Protective index, ratio of TD50 for CF1 albino mouse neurotoxicity to ED50 for protection against 6 Hz electroshock-induced seizure in CF1 albino mouse2014Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23
Seizure prevention by the naturally occurring phenols, carvacrol and thymol in a partial seizure-psychomotor model.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1246364Anticonvulsant activity in ip dosed albino CD-1 mouse assessed as protection against maximal electroshock-induced seizure measured as time to peak effect2015European journal of medicinal chemistry, Sep-18, Volume: 102Design, synthesis and biological activity of new amides derived from 3-methyl-3-phenyl-2,5-dioxo-pyrrolidin-1-yl-acetic acid.
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID666680Neurotoxicity in Kunming mouse at 300 mg/kg, ip after 4 hrs by rotorod test2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and anticonvulsant activity of ethyl 1-(2-arylhydrazinecarboxamido)-2,2-dimethylcyclopropanecarboxylate derivatives.
AID1269468Anticonvulsant activity in Swiss mouse assessed as prolong latency to first seizure episode at 120 mg/kg pretreated for 0.25 hrs measured after 30 mins by subcutaneous pentylenetetrazole seizure test2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
New hybrid molecules with anticonvulsant and antinociceptive activity derived from 3-methyl- or 3,3-dimethyl-1-[1-oxo-1-(4-phenylpiperazin-1-yl)propan-2-yl]pyrrolidine-2,5-diones.
AID1452172Protection index, ratio of TD50 for neurotoxicity in ip dosed Albino Swiss CD-1 mouse to ED50 for ip dosed pentylenetetrazole induced seizure Albino Swiss CD-1 mouse model
AID727848Neurotoxicity against Swiss albino mouse by rotarod test at 300 mg/kg, ip after 4 hrs2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Novel limonene and citral based 2,5-disubstituted-1,3,4-oxadiazoles: a natural product coupled approach to semicarbazones for antiepileptic activity.
AID382211Anticonvulsant activity in ip dosed CF1 albino mouse assessed as inhibition of maximal electroshock-induced electrical stimulus at 300 mg/kg after 4 hrs2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Design, synthesis, and anticonvulsant activity of N-phenylamino derivatives of 3,3-dialkyl-pyrrolidine-2,5-diones and hexahydro-isoindole-1,3-diones.
AID511976Anticonvulsant activity in Kunming rat assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 30 mg/kg, po after 0.25 hrs2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis and anticonvulsant activity of new 6-methyl-1-substituted-4,6-diazaspiro[2.4]heptane-5,7-diones.
AID189459Protective index (TD50/ED50) was determined against MES induced seizure in rat.1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Synthesis and evaluation of N-(phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents.
AID657392Anticonvulsant activity in ip dosed Swiss albino mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures after 0.5 hrs2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Design, synthesis and anticonvulsant activities of novel 1-(substituted/unsubstituted benzylidene)-4-(4-(6,8-dibromo-2-(methyl/phenyl)-4-oxoquinazolin-3(4H)-yl)phenyl) semicarbazide derivatives.
AID626656Anticonvulsant activity in albino Carworth Farms No.1 mouse assessed as protection against electric-current for 3 secs-induced seizure at 100 mg/kg, ip after 0.5 hrs by 6Hz minimal clonic seizure test2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and anticonvulsant activity of novel 2,6-diketopiperazine derivatives. Part 1: perhydropyrrole[1,2-a]pyrazines.
AID1269471Anticonvulsant activity in ip dosed Swiss mouse assessed as reduction in clonic seizures at 0.25 hrs by subcutaneous pentylenetetrazole seizure test2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
New hybrid molecules with anticonvulsant and antinociceptive activity derived from 3-methyl- or 3,3-dimethyl-1-[1-oxo-1-(4-phenylpiperazin-1-yl)propan-2-yl]pyrrolidine-2,5-diones.
AID394947Neurotoxicity in Swiss albino mouse at 300 mg/kg, ip after 0.5 hrs by rotarod test2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis of some novel N4-(naphtha[1,2-d]thiazol-2-yl)semicarbazides as potential anticonvulsants.
AID1229800Protective index, ratio of neurotoxic TD50 in Swiss mouse by by Chimney test to anticonvulsant ED50 in Swiss mouse measured at 0.25 hrs of time to peak effect by subcutaneous pentylenetetrazole seizure test2015Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
Design, synthesis, and anticonvulsant activity of new hybrid compounds derived from 2-(2,5-dioxopyrrolidin-1-yl)propanamides and 2-(2,5-dioxopyrrolidin-1-yl)butanamides.
AID487192Neurotoxicity in Albino mouse assessed as minimal motor impairment at 300 mg/kg, ip after 0.5 hrs by rotarod test2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis, anticonvulsant and toxicity screening of newer pyrimidine semicarbazone derivatives.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID50620Compound was evaluated for effective dose by subcutaneous pentylenetetrazole test after intraperitoneal administration of the compound.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and anticonvulsant activity of imidooxy derivatives.
AID1229795Anticonvulsant activity in ip dosed Swiss mouse assessed as protection against seizures measured at 0.25 hrs of time to peak effect by maximal electroshock test2015Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
Design, synthesis, and anticonvulsant activity of new hybrid compounds derived from 2-(2,5-dioxopyrrolidin-1-yl)propanamides and 2-(2,5-dioxopyrrolidin-1-yl)butanamides.
AID286859Analgesic activity in Swiss Albino mouse assessed as inhibition of acetic acid-induced writhing responses at 100 mg/kg, ip2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Discovery of 4-aminobutyric acid derivatives possessing anticonvulsant and antinociceptive activities: a hybrid pharmacophore approach.
AID1285350Neurotoxicity in CD1 albino mouse assessed as acute motor impairment at 300 mg/kg, ip measured after 0.5 hrs by rotarod test2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Synthesis, and anticonvulsant activity of new amides derived from 3-methyl- or 3-ethyl-3-methyl-2,5-dioxo-pyrrolidin-1-yl-acetic acids.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID111838Compound was evaluated for the ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 40 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID628635Neurotoxicity in CF1 albino mouse assessed as motor impairment at 300 mg/kg, ip after 4 hrs by rotarod test2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and anticonvulsant properties of new acetamide derivatives of phthalimide, and its saturated cyclohexane and norbornene analogs.
AID390816Inhibition of T-type calcium channel alpha1I by FLIPR2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.
AID409946Inhibition of human recombinant MAOB at 100 uM by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID287123Anticonvulsant activity against subcutaneous strychnine-induced seizure in Albino CF1 mouse at 300 mg/kg, ip after 0.5 hrs2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
Design and synthesis of anticonvulsants from a combined phthalimide-GABA-anilide and hydrazone pharmacophore.
AID1285356Anticonvulsant activity in ip dosed CD1 albino mouse assessed as time to peak effect2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Synthesis, and anticonvulsant activity of new amides derived from 3-methyl- or 3-ethyl-3-methyl-2,5-dioxo-pyrrolidin-1-yl-acetic acids.
AID113986Anticonvulsant activity was determined by subcutaneous picrotoxin test (CD97=3.15 mg/kg) (Phase V Pharmacological Evaluation)1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Functionalized DL-amino acid derivatives. Potent new agents for the treatment of epilepsy.
AID111827Compound was evaluated for the ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 10 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID516037Anticonvulsant activity in Sprague-Dawley rat assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 50 mg/kg po after 0.25 hrs2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Design, synthesis, and anticonvulsant activity of new N-Mannich bases derived from spirosuccinimides and spirohydantoins.
AID626747Anticonvulsant activity in po dosed albino Sprague-Dawley rat assessed as protection against maximal electroshock-induced seizure after 0.25 hrs2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and anticonvulsant activity of novel 2,6-diketopiperazine derivatives. Part 1: perhydropyrrole[1,2-a]pyrazines.
AID683953Anticonvulsant activity in ip dosed CF-1 albino mouse assessed as protection against subcutaneous pentylenetetrazol-induced seizures measured after 0.5 hrs2012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Synthesis and anticonvulsant activity of new N-Mannich bases derived from 3-(2-fluorophenyl)- and 3-(2-bromophenyl)-pyrrolidine-2,5-diones. Part II.
AID231256Protective index (PI), anticonvulsant activity, ratio of TD50/ED50 value in maximal electroconvulsive shock seizure (MES) test1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Triazolines. 14. 1,2,3-Triazolines and triazoles, a new class of anticonvulsants. Drug design and structure-activity relationships.
AID1269470Anticonvulsant activity in ip dosed Swiss mouse assessed as protection against maximal electroshock-induced seizures at 0.25 hrs2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
New hybrid molecules with anticonvulsant and antinociceptive activity derived from 3-methyl- or 3,3-dimethyl-1-[1-oxo-1-(4-phenylpiperazin-1-yl)propan-2-yl]pyrrolidine-2,5-diones.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID511894Neurotoxicity in Kunming rat assessed as minimum motor impairment at 30 mg/kg, po after 0.5 hrs by rotarod test2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis and anticonvulsant activity of new 6-methyl-1-substituted-4,6-diazaspiro[2.4]heptane-5,7-diones.
AID489791Anticonvulsant activity against subcutaneous pentylenetetrazole-induced seizures in ip dosed Swiss albino mouse assessed as minimum effective dose after 0.5 hrs2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Combating oxidative stress in epilepsy: design, synthesis, quantum chemical studies and anticonvulsant evaluation of 1-(substituted benzylidene/ethylidene)-4-(naphthalen-1-yl)semicarbazides.
AID1576063Anticonvulsant activity in mouse assessed as MES-induced tonic seizures at 10 to 100 mg/kg, ip administered 45 mins before electrical stimulation2019MedChemComm, Aug-01, Volume: 10, Issue:8
Derivatives of a new heterocyclic system - pyrano[3,4-
AID118795Retention for passive avoidance learning in mice at dose 80 mg/kg1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Cognition-activating properties of 3-(Aryloxy)pyridines.
AID780686Neurotoxicity in ip dosed albino mouse minimal clonic seizure model assessed as minimal motor impairment by rotorod test2013Bioorganic & medicinal chemistry letters, Nov-15, Volume: 23, Issue:22
Structure-activity relationships of the aromatic site in novel anticonvulsant pyrrolo[1,2-a]pyrazine derivatives.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID394938Anticonvulsant activity in ip dosed Swiss albino mouse assessed as minimum drug concentration required for inhibition of pentylenetetrazole-induced seizures in half or more of mouse after 0.5 hrs by scPTZ test2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis of some novel N4-(naphtha[1,2-d]thiazol-2-yl)semicarbazides as potential anticonvulsants.
AID382388Neurotoxicity in mouse at 300 mg/kg, ip after 4 hrs by rotarod test2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Synthesis and CNS depressant activity of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones.
AID779006Anticonvulsant activity against maximal subcutaneous pentylenetetrazole-induced convulsion in po dosed albino Sprague-Dawley rat assessed as time to peak effect2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Design, synthesis and anticonvulsant properties of new N-Mannich bases derived from 3-phenylpyrrolidine-2,5-diones.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID683947Neurotoxicity in CF-1 albino mouse assessed as motor impairment at 300 mg/kg, ip measured after 0.5 hrs by rotarod test2012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Synthesis and anticonvulsant activity of new N-Mannich bases derived from 3-(2-fluorophenyl)- and 3-(2-bromophenyl)-pyrrolidine-2,5-diones. Part II.
AID113903Median Effective dose was evaluated by Subcutaneous pentylenetetrazole seizure test in mice by oral administration1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Synthesis and evaluation of N-(phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents.
AID1711738Protection index, ratio of TD50 for neurotoxicity in ip dosed mouse to ED50 for anticonvulsant activity in ip dosed mouse measured after 0.25 hrs by subcutaneous pentylenetetrazole test2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Synthesis and evaluation of anticonvulsant properties of new N-Mannich bases derived from 3-(1-phenylethyl)- and 3-benzyl-pyrrolidine-2,5-dione.
AID1135316Neurotoxicity in ip dosed albino CD-1 mouse by rotarod test1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
3,4-Methylenedioxyphenyl-, isopropylidenedioxyphenyl-, and benzyl-substituted chiral 2-aminosuccinimides and 3-aminopyrrolidines. Stereoselective investigations of potential anti-parkinsonian, antipsychotic, and anticonvulsant activities.
AID1191602Anticonvulsant activity in Swiss albino mouse assessed as reduction in electrical stimulus-induced seizures at 300 mg/kg, ip after 0.5 hrs by maximal electroshock seizure test2015Bioorganic & medicinal chemistry letters, Mar-01, Volume: 25, Issue:5
Design, synthesis and pharmacological evaluation of N-[4-(4-(alkyl/aryl/heteroaryl)-piperazin-1-yl)-phenyl]-carbamic acid ethyl ester derivatives as novel anticonvulsant agents.
AID132653The effective dose of compound was tested against subcutaneous administered Metrazol induced seizures in mice1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Synthesis and anticonvulsant activity of 2-benzylglutarimides.
AID1195114Anticonvulsant activity in intraperitoneally dosed Albino Swiss CD1 mouse by subcutaneous pentylenetetrazole test2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
Design, synthesis and biological evaluation of new hybrid anticonvulsants derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide derivatives.
AID637064Anticonvulsant activity in Kunming mouse assessed as protection against maximal electroshock-induced seizure at 300 mg/kg, ip after 4 hrs2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and anticonvulsant activity of 1-(8-(benzyloxy)quinolin-2-yl)-6-substituted-4,6-diazaspiro[2,4]heptane-5,7-diones.
AID1720863Neurotoxicity in ip injected albino mouse2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants.
AID623089Anticonvulsant activity in po dosed Sprague-Dawley albino rat assessed as protection against subcutaneous pentylenetetrazole-induced seizures2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Synthesis and anticonvulsant activity of new N-Mannich bases derived from 5-cyclopropyl-5-phenyl- and 5-cyclopropyl-5-(4-chlorophenyl)-imidazolidine-2,4-diones.
AID1863991Protective index, ratio of TD50 for toxicity in CD-1 seizure mouse model assessed as effect on motor coordination administered ip measured after 0.5 hrs for 3 mins by rotarod test to ED50 for antiseizure activity against ScPTZ-induced seizure ip dosed CD-
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1196890Anticonvulsant activity in Kunming mouse assessed as protection against maximal electroshock-induced seizures measured as abolition of hind limb tonic extension spasm at 300 mg/kg, ip after 0.5 hrs2015European journal of medicinal chemistry, Mar-06, Volume: 92Design, synthesis and pharmacological evaluation of novel N-(2-(1, 1-dimethyl-5, 7-dioxo-4, 6-diazaspiro[2.4]heptan-6-yl)ethyl) sulfonamide derivatives as potential anticonvulsant agents.
AID779020Neurotoxicity in albino CF1 mouse assessed as minimum motor impairment at 300 mg/kg, ip measured after 4 hrs by rotorod test2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Design, synthesis and anticonvulsant properties of new N-Mannich bases derived from 3-phenylpyrrolidine-2,5-diones.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID779010Neurotoxicity in po dosed albino Sprague-Dawley rat assessed as minimum motor impairment by rotorod test2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Design, synthesis and anticonvulsant properties of new N-Mannich bases derived from 3-phenylpyrrolidine-2,5-diones.
AID364304Neurotoxicity in mouse assessed as minimal motor impairment at 300 mg/kg, ip after 0.5 hrs by rotarod test2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
CNS depressant and anticonvulsant activities of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones.
AID621010Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures after 0.5 hrs2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Synthesis and anticonvulsant activity of new 1-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]pyrrolidine-2,5-diones.
AID1195117Protective index, ratio of neurotoxic TD50 in Albino Swiss CD1 mouse by rotarod test to anticonvulsant ED50 in Albino Swiss CD1 mouse by subcutaneous pentylenetetrazole test2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
Design, synthesis and biological evaluation of new hybrid anticonvulsants derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide derivatives.
AID487181Anticonvulsant activity in ip dosed Albino mouse assessed as protection against scPTZ-induced seizure after 4 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis, anticonvulsant and toxicity screening of newer pyrimidine semicarbazone derivatives.
AID1065306Protective index, ratio of TD50 for neurotoxicity to ED50 for protection against pentylenetetrazole-induced seizure in albino rat after 2 hrs2013European journal of medicinal chemistry, Sep, Volume: 67Design, synthesis and anticonvulsant evaluation of N-(benzo[d]thiazol-2-ylcarbamoyl)-2-methyl-4-oxoquinazoline-3(4H)-carbothioamide derivatives: a hybrid pharmacophore approach.
AID396627Anticonvulsant activity in Swiss albino mouse assessed as inhibition of subcutaneous picrotoxin-induced seizures at 300 mg/kg, ip administered 30 mins before PIC challenge measured after 0.5 hrs post PIC challenge2008European journal of medicinal chemistry, Dec, Volume: 43, Issue:12
Newer GABA derivatives for the treatment of epilepsy including febrile seizures: a bioisosteric approach.
AID516045Neurotoxicity in po dosed Sprague-Dawley rat by rotarod test2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Design, synthesis, and anticonvulsant activity of new N-Mannich bases derived from spirosuccinimides and spirohydantoins.
AID623226Anticonvulsant activity in CF1 albino mouse assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip after 4 hrs2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Synthesis and anticonvulsant activity of new N-Mannich bases derived from 5-cyclopropyl-5-phenyl- and 5-cyclopropyl-5-(4-chlorophenyl)-imidazolidine-2,4-diones.
AID727990Antiepileptic activity in ip dosed Swiss albino mouse assessed as protection against scPTZ-induced seizures after 4 hrs2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Novel limonene and citral based 2,5-disubstituted-1,3,4-oxadiazoles: a natural product coupled approach to semicarbazones for antiepileptic activity.
AID287128Anticonvulsant activity against intraperitoneal picrotoxin-induced seizure in Albino CF1 mouse at 300 mg/kg, ip after 0.5 hrs2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
Design and synthesis of anticonvulsants from a combined phthalimide-GABA-anilide and hydrazone pharmacophore.
AID1576061Protection index, ratio of TD50 for neurotoxicity in ip dosed mouse to ED50 for anticonvulsant activity in ip dosed mouse2019MedChemComm, Aug-01, Volume: 10, Issue:8
Derivatives of a new heterocyclic system - pyrano[3,4-
AID545519Anticonvulsant activity in ip dosed mouse assessed as inhibition of maximum electric shock-induced hind limb tonic extension after 0.5 hrs2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis and anticonvulsant activity of N-3-arylamide substituted 5,5-cyclopropanespirohydantoin derivatives.
AID1183228Anticonvulsant activity in albino Swiss mouse assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip at 4 hrs2014European journal of medicinal chemistry, Sep-12, Volume: 84Design and synthesis of new of 3-(benzo[d]isoxazol-3-yl)-1-substituted pyrrolidine-2, 5-dione derivatives as anticonvulsants.
AID1720891Anticonvulsant activity in KunMing mouse assessed as protection against pentylenetetrazole-induced seizure by maximal electroshock seizure test2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants.
AID1269444Neurotoxicity in ip dosed Swiss mouse seizure model assessed as motor impairment pretreated for 0.25 hrs measured within 60 s by chimney test2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
New hybrid molecules with anticonvulsant and antinociceptive activity derived from 3-methyl- or 3,3-dimethyl-1-[1-oxo-1-(4-phenylpiperazin-1-yl)propan-2-yl]pyrrolidine-2,5-diones.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID487184Anticonvulsant activity in Albino mouse assessed as protection against maximal electric shock-induced seizure at 300 mg/kg, ip after 0.5 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis, anticonvulsant and toxicity screening of newer pyrimidine semicarbazone derivatives.
AID540231Dose normalised AUC in dog after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID657399Neurotoxicity in Swiss albino mouse assessed as motor impairment at 300 mg/kg, ip after 4 hrs by rotorod test2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Design, synthesis and anticonvulsant activities of novel 1-(substituted/unsubstituted benzylidene)-4-(4-(6,8-dibromo-2-(methyl/phenyl)-4-oxoquinazolin-3(4H)-yl)phenyl) semicarbazide derivatives.
AID1065345Anticonvulsant activity in albino mouse assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip measured after 0.5 hrs2013European journal of medicinal chemistry, Sep, Volume: 67Design, synthesis and anticonvulsant evaluation of N-(benzo[d]thiazol-2-ylcarbamoyl)-2-methyl-4-oxoquinazoline-3(4H)-carbothioamide derivatives: a hybrid pharmacophore approach.
AID489803Anticonvulsant activity against subcutaneous pentylenetetrazole-induced seizures in Wistar albino rat at 50 mg/kg, ip after 0.25 hrs2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Combating oxidative stress in epilepsy: design, synthesis, quantum chemical studies and anticonvulsant evaluation of 1-(substituted benzylidene/ethylidene)-4-(naphthalen-1-yl)semicarbazides.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID516044Anticonvulsant activity in po dosed Sprague-Dawley rat assessed as protection against subcutaneous pentylenetetrazole-induced seizures2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Design, synthesis, and anticonvulsant activity of new N-Mannich bases derived from spirosuccinimides and spirohydantoins.
AID623178Neurotoxicity in CF1 albino mouse assessed as impair in motor coordination at 300 mg/kg, ip after 4 hrs by rotarod test2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Synthesis and anticonvulsant activity of new N-Mannich bases derived from 5-cyclopropyl-5-phenyl- and 5-cyclopropyl-5-(4-chlorophenyl)-imidazolidine-2,4-diones.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID623167Anticonvulsant activity in Sprague-Dawley albino rat assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 50 mg/kg, po after 0.25 hrs2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Synthesis and anticonvulsant activity of new N-Mannich bases derived from 5-cyclopropyl-5-phenyl- and 5-cyclopropyl-5-(4-chlorophenyl)-imidazolidine-2,4-diones.
AID1065343Anticonvulsant activity in albino mouse assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip measured after 4 hrs2013European journal of medicinal chemistry, Sep, Volume: 67Design, synthesis and anticonvulsant evaluation of N-(benzo[d]thiazol-2-ylcarbamoyl)-2-methyl-4-oxoquinazoline-3(4H)-carbothioamide derivatives: a hybrid pharmacophore approach.
AID113902Median Effective dose was evaluated by Maximal electroshock seizure (MES) test in mice by oral administration up to 2000 mg/kg; f=no protection1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Synthesis and evaluation of N-(phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1863976Antiseizure activity against electrical stimulus induced seizure in ip dosed CD-1 mouse model assessed as reduction in hindlimb tonic extension pretreated for 0.25 hrs by maximal electroshock seizure test
AID621008Anticonvulsant activity in albino CF1 mouse assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip after 0.5 hrs2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Synthesis and anticonvulsant activity of new 1-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]pyrrolidine-2,5-diones.
AID1452159Anticonvulsant activity in ip dosed Albino Swiss CD-1 mouse assessed as protection against maximal electroshock-induced seizures pretreated up to 2 hrs followed by 50 Hz current induction for 2 secs measured at time to peak effect
AID113639ED50 was evaluated from MES test in mice by delivering intraperitoneally and the value was determined at peak time effect or peak neurologic effect.1991Journal of medicinal chemistry, Jun, Volume: 34, Issue:6
Synthesis and anticonvulsant activity of 2-iminohydantoins.
AID1720892Neurotoxicity in KunMing mouse by rotarod test2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants.
AID511974Neurotoxicity in Kunming rat assessed as minimum motor impairment at 30 mg/kg, po after 2 hrs by rotarod test2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis and anticonvulsant activity of new 6-methyl-1-substituted-4,6-diazaspiro[2.4]heptane-5,7-diones.
AID477740Neurotoxicity in Swiss albino mouse at 300 mg/kg, ip after 0.5 hrs2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening.
AID127822The effective dose of compound was tested against subcutaneous administered Metrazol induced seizures after intraperitoneal administration.1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Synthesis and anticonvulsant activity of 2-benzylglutarimides.
AID727849Neurotoxicity against Swiss albino mouse by rotarod test at 300 mg/kg, ip after 0.5 hrs2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Novel limonene and citral based 2,5-disubstituted-1,3,4-oxadiazoles: a natural product coupled approach to semicarbazones for antiepileptic activity.
AID623094Neurotoxicity in Sprague-Dawley albino rat assessed as motor impairment at 50 mg/kg, po after 1 hrs by rotarod test2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Synthesis and anticonvulsant activity of new N-Mannich bases derived from 5-cyclopropyl-5-phenyl- and 5-cyclopropyl-5-(4-chlorophenyl)-imidazolidine-2,4-diones.
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1304288Anticonvulsant activity in albino Swiss mouse by maximal electroshock seizure test2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Design, synthesis and anticonvulsant activity of new hybrid compounds derived from N-phenyl-2-(2,5-dioxopyrrolidin-1-yl)-propanamides and -butanamides.
AID286853Anticonvulsant activity in Swiss Albino mouse at 300 mg/kg, ip after 4 hrs by scPIC test2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Discovery of 4-aminobutyric acid derivatives possessing anticonvulsant and antinociceptive activities: a hybrid pharmacophore approach.
AID382178Anticonvulsant activity in ip dosed CF1 albino mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced electrical stimulus after 0.5 hr2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Design, synthesis, and anticonvulsant activity of N-phenylamino derivatives of 3,3-dialkyl-pyrrolidine-2,5-diones and hexahydro-isoindole-1,3-diones.
AID168887Time to peak effect in Rats was evaluated by Subcutaneous pentylenetetrazole seizure test in hours by oral administration1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Synthesis and evaluation of N-(phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents.
AID136516Latency to the protection against lethality by picrotoxin was measured and evaluated as a percent of the control in mice.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Synthesis and anticonvulsant activity of 1-acyl-2-pyrrolidinone derivatives.
AID1285342Anticonvulsant activity in CD1 albino mouse assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip after 0.5 hrs2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Synthesis, and anticonvulsant activity of new amides derived from 3-methyl- or 3-ethyl-3-methyl-2,5-dioxo-pyrrolidin-1-yl-acetic acids.
AID1742406Neurotoxicity in Kunming mouse at 100 mg/kg, ip measured after 30 mins by rotarod test
AID305062Anticonvulsant activity against maximal electroshock-induced seizure in Albino mouse at 300 mg/kg, ip after 4 hrs2007Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1
Synthesis and anticonvulsant activity of sulfonamide derivatives-hydrophobic domain.
AID779026Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against subcutaneous pentylenetetrazole-induced convulsion in half or more animals measured after 4 hrs2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Design, synthesis and anticonvulsant properties of new N-Mannich bases derived from 3-phenylpyrrolidine-2,5-diones.
AID113907Median effective dose was evaluated by subcutaneous pentylenetetrazole seizure test through intraperitoneal administration1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Synthesis and evaluation of N-(phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents.
AID287130Anticonvulsant activity against intraperitoneal picrotoxin-induced seizure in Albino CF1 mouse at 300 mg/kg, ip after 4 hrs2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
Design and synthesis of anticonvulsants from a combined phthalimide-GABA-anilide and hydrazone pharmacophore.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID767980Antimutagenic activity in Vibrio harveyi BB7 assessed as inhibition of 4-nitroquinoline-N-oxide-induced mutation2013European journal of medicinal chemistry, Aug, Volume: 66Synthesis and biological properties of new N-Mannich bases derived from 3-methyl-3-phenyl- and 3,3-dimethyl-succinimides. Part V.
AID226943Protectivity index is the ratio of TD50 /MES ED50 from Phase-IV evaluation1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Functionalized DL-amino acid derivatives. Potent new agents for the treatment of epilepsy.
AID396633Neurotoxicity in Swiss albino mouse assessed as inability of animal to maintain equilibrium on the rod for at least 1 min at 300 mg/kg, ip after 4 hrs by rotarod test2008European journal of medicinal chemistry, Dec, Volume: 43, Issue:12
Newer GABA derivatives for the treatment of epilepsy including febrile seizures: a bioisosteric approach.
AID780693Anticonvulsant activity in ip dosed albino mouse assessed as time of peak effect for protection against 6 Hz psychomotor seizure by minimal clonic seizure test2013Bioorganic & medicinal chemistry letters, Nov-15, Volume: 23, Issue:22
Structure-activity relationships of the aromatic site in novel anticonvulsant pyrrolo[1,2-a]pyrazine derivatives.
AID225289Effective dose was measured in rat by maximal electroshock method by ip administration1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis and CLOGP correlation of imidooxy anticonvulsants.
AID1711720Anti-convulsant activity in ip dosed mouse assessed as protection against psychomotor seizures measured after 0.25 hrs by 6 Hz limbic seizure test2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Synthesis and evaluation of anticonvulsant properties of new N-Mannich bases derived from 3-(1-phenylethyl)- and 3-benzyl-pyrrolidine-2,5-dione.
AID1711718Anticonvulsant activity in ip dosed mouse assessed as protection against ScPTZ-induced epilepsy measured after 0.25 hrs by subcutaneous pentylenetetrazole test2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Synthesis and evaluation of anticonvulsant properties of new N-Mannich bases derived from 3-(1-phenylethyl)- and 3-benzyl-pyrrolidine-2,5-dione.
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID226708Protective index, measure of ratio of TD50 and ED501996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
3,3-Dialkyl- and 3-alkyl-3-benzyl-substituted 2-pyrrolidinones: a new class of anticonvulsant agents.
AID180907The effective dose of compound was tested against subcutaneous administered Metrazol induced seizures in rat.1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Synthesis and anticonvulsant activity of 2-benzylglutarimides.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID623095Neurotoxicity in Sprague-Dawley albino rat assessed as motor impairment at 50 mg/kg, po after 0.5 hrs by rotarod test2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Synthesis and anticonvulsant activity of new N-Mannich bases derived from 5-cyclopropyl-5-phenyl- and 5-cyclopropyl-5-(4-chlorophenyl)-imidazolidine-2,4-diones.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1576059Neurotoxicity in ip dosed mouse assessed as myorelaxation measured for 2 mins by rotarod test2019MedChemComm, Aug-01, Volume: 10, Issue:8
Derivatives of a new heterocyclic system - pyrano[3,4-
AID626749Neurotoxicity in po dosed albino Sprague-Dawley rat assessed as motor impairment after 0.25 hrs by rotarod test2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and anticonvulsant activity of novel 2,6-diketopiperazine derivatives. Part 1: perhydropyrrole[1,2-a]pyrazines.
AID51428Compound was evaluated for toxic dose at peak neurologic deficit after intraperitoneal administration of the compound.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and anticonvulsant activity of imidooxy derivatives.
AID779014Anticonvulsant activity in po dosed albino Sprague-Dawley rat assessed as protection against maximal electroshock-induced seizures2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Design, synthesis and anticonvulsant properties of new N-Mannich bases derived from 3-phenylpyrrolidine-2,5-diones.
AID117223Median lethal dose was evaluated by mortality after 24 hr through ip injection administration1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Synthesis and evaluation of N-(phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1398112Inhibition of T-type calcium channel (unknown origin)2018Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15
Design and synthesis of novel anti-hyperalgesic agents based on 6-prenylnaringenin as the T-type calcium channel blockers.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1191606Neurological toxicity in Swiss albino mouse assessed as motor impairment at at 300 mg/kg, ip after 0.5 hrs by rotarod test2015Bioorganic & medicinal chemistry letters, Mar-01, Volume: 25, Issue:5
Design, synthesis and pharmacological evaluation of N-[4-(4-(alkyl/aryl/heteroaryl)-piperazin-1-yl)-phenyl]-carbamic acid ethyl ester derivatives as novel anticonvulsant agents.
AID394936Anticonvulsant activity against maximal electroshock-induced seizures in Swiss albino mouse at 300 mg/kg, ip after 0.5 hrs by MES test2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis of some novel N4-(naphtha[1,2-d]thiazol-2-yl)semicarbazides as potential anticonvulsants.
AID128038Compound was tested for anticonvulsant activity against maximal electroshock-induced clonic seizures in mice at 50mA, 200 ms1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
2-Phenyl-3H-imidazo[4,5-b]pyridine-3-acetamides as non-benzodiazepine anticonvulsants and anxiolytics.
AID516043Anticonvulsant activity in po dosed Sprague-Dawley rat assessed as protection against maximal electroshock-induced seizures2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Design, synthesis, and anticonvulsant activity of new N-Mannich bases derived from spirosuccinimides and spirohydantoins.
AID22950Time of peak effect (TPE) for activity1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and anticonvulsant activity of imidooxy derivatives.
AID1378589Anticonvulsant activity in ip dosed CF1 mouse assessed as protection against 32 mA current-induced seizure after 15 mins by 6 Hz psychomotor test2017Journal of natural products, 08-25, Volume: 80, Issue:8
Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.
AID221089Time of peak effect of toxicity of compound was measured by both MES and sc Met test in mice1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis and CLOGP correlation of imidooxy anticonvulsants.
AID396411Anticonvulsant activity in ip dosed Swiss albino mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures administered 30 mins before PTZ challenge measured after 0.5 hrs post PTZ challenge2008European journal of medicinal chemistry, Dec, Volume: 43, Issue:12
Newer GABA derivatives for the treatment of epilepsy including febrile seizures: a bioisosteric approach.
AID657394Anticonvulsant activity in ip dosed Swiss albino mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures after 4 hrs2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Design, synthesis and anticonvulsant activities of novel 1-(substituted/unsubstituted benzylidene)-4-(4-(6,8-dibromo-2-(methyl/phenyl)-4-oxoquinazolin-3(4H)-yl)phenyl) semicarbazide derivatives.
AID1544809Anticonvulsant activity in ip dosed albino mouse model of subcutaneous pentylenetetrazole-induced seizure assessed as failure to observe even a single episode of clonic spasms for at least 5 secs pretreated for 0.5 hrs followed by pentylenetetrazole induc2019Bioorganic & medicinal chemistry letters, 07-15, Volume: 29, Issue:14
Novel benzothiazole hydrazine carboxamide hybrid scaffolds as potential in vitro GABA AT enzyme inhibitors: Synthesis, molecular docking and antiepileptic evaluation.
AID1065316Neurotoxicity in po dosed albino mouse after 1 hr2013European journal of medicinal chemistry, Sep, Volume: 67Design, synthesis and anticonvulsant evaluation of N-(benzo[d]thiazol-2-ylcarbamoyl)-2-methyl-4-oxoquinazoline-3(4H)-carbothioamide derivatives: a hybrid pharmacophore approach.
AID545524Neurotoxicity against ip dosed mouse by rotarod test after 4 hrs2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis and anticonvulsant activity of N-3-arylamide substituted 5,5-cyclopropanespirohydantoin derivatives.
AID767984Induction of mutagenecity in Vibrio harveyi BB72013European journal of medicinal chemistry, Aug, Volume: 66Synthesis and biological properties of new N-Mannich bases derived from 3-methyl-3-phenyl- and 3,3-dimethyl-succinimides. Part V.
AID629225Antiepileptic activity in ip dosed Swiss albino mouse assessed as dose required to protect against subcutaneous pentylenetetrazol-induced clonic seizures after 0.5 hrs2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Design, synthesis and antiepileptic properties of novel 1-(substituted benzylidene)-3-(1-(morpholino/piperidino methyl)-2,3-dioxoindolin-5-yl)urea derivatives.
AID623092Neurotoxicity in Sprague-Dawley albino rat assessed as motor impairment at 50 mg/kg, po after 4 hrs by rotarod test2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Synthesis and anticonvulsant activity of new N-Mannich bases derived from 5-cyclopropyl-5-phenyl- and 5-cyclopropyl-5-(4-chlorophenyl)-imidazolidine-2,4-diones.
AID364289Anticonvulsant activity in mouse at 300 mg/kg, ip after 4 hrs by MES test2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
CNS depressant and anticonvulsant activities of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones.
AID489287Anticonvulsant activity against maximal electroshock-induced seizures in Swiss albino mouse at 300 mg/kg, ip after 0.5 hrs2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Novel semicarbazones based 2,5-disubstituted-1,3,4-oxadiazoles: one more step towards establishing four binding site pharmacophoric model hypothesis for anticonvulsant activity.
AID779008Protection index, ratio of TD50 for neurotoxicity in po dosed albino Sprague-Dawley rat by rotorod test to ED50 for anticonvulsant activity in po dosed albino Sprague-Dawley rat by scPTZ test2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Design, synthesis and anticonvulsant properties of new N-Mannich bases derived from 3-phenylpyrrolidine-2,5-diones.
AID287118Anticonvulsant activity against subcutaneous pentylenetetrazole-induced seizure in Albino CF1 mouse at 300 mg/kg, ip after 0.5 hrs2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
Design and synthesis of anticonvulsants from a combined phthalimide-GABA-anilide and hydrazone pharmacophore.
AID168885Time to peak effect in Rats was evaluated by Maximal electroshock seizure (MES) test in hours by oral administration1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Synthesis and evaluation of N-(phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1156736Anticonvulsant activity against pentylenetetrazole-induced seizure in albino Swiss (CD-1) mouse assessed as decrease in mortality rate at 100 mg/kg, ip administered 60 mins prior to PTZ challenge2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis, biological evaluation and structure-activity relationship of new GABA uptake inhibitors, derivatives of 4-aminobutanamides.
AID779007Anticonvulsant activity against maximal electroshock-induced seizures in po dosed albino Sprague-Dawley rat assessed as time to peak effect2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Design, synthesis and anticonvulsant properties of new N-Mannich bases derived from 3-phenylpyrrolidine-2,5-diones.
AID628630Anticonvulsant activity in CF1 albino mouse assessed as protection against maximal electroshock at 300 mg/kg, ip after 0.5 hrs2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and anticonvulsant properties of new acetamide derivatives of phthalimide, and its saturated cyclohexane and norbornene analogs.
AID621016Neurotoxicity in albino CF1 mouse assessed as motor impairment at 300 mg/kg, ip after 0.5 hrs by rotarod test2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Synthesis and anticonvulsant activity of new 1-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]pyrrolidine-2,5-diones.
AID621017Neurotoxicity in albino CF1 mouse assessed as motor impairment at 300 mg/kg, ip after 4 hrs by rotarod test2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Synthesis and anticonvulsant activity of new 1-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]pyrrolidine-2,5-diones.
AID1264976Anticonvulsant activity in Swiss albino mouse assessed as reduction of maximal electroshock-induced seizure at 300 mg/kg, ip after 0.5 hrs2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis of 2,6-dicarbethoxy-3,5-diaryltetrahydro-1,4-thiazine-1,1-dioxide derivatives as potent anticonvulsant agents.
AID1143164Anticonvulsant activity in ip dosed Swiss albino mouse assessed as protection against pentylenetetrazole-induced seizures after 0.5 hrs2014European journal of medicinal chemistry, Jun-10, Volume: 80Anticonvulsant evaluation of clubbed indole-1,2,4-triazine derivatives: a synthetic approach.
AID111843Ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 80 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID132472The compound was tested for anticonvulsant activity against (subcutaneous administered) bicuculline induced seizures after intraperitoneal administration1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Synthesis and anticonvulsant activity of 2-benzylglutarimides.
AID477737Anticonvulsant activity in Swiss albino mouse assessed as inhibition of maximum electric shock-induced motor impairment at 300 mg/kg, ip after 4 hrs2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening.
AID477353Anticonvulsant activity in ip dosed Swiss albino mouse assessed as inhibition of PTZ-induced motor impairment after 4 hrs2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening.
AID136262Neurotoxicity against mice in rotarod test1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
2-Phenyl-3H-imidazo[4,5-b]pyridine-3-acetamides as non-benzodiazepine anticonvulsants and anxiolytics.
AID394937Anticonvulsant activity against maximal electroshock-induced seizures in Swiss albino mouse at 300 mg/kg, ip after 4 hrs by MES test2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis of some novel N4-(naphtha[1,2-d]thiazol-2-yl)semicarbazides as potential anticonvulsants.
AID1156738Anticonvulsant activity against pentylenetetrazole-induced seizure in albino Swiss (CD-1) mouse assessed as decrease in seizure episodes at 100 mg/kg, ip administered 60 mins prior to PTZ challenge2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis, biological evaluation and structure-activity relationship of new GABA uptake inhibitors, derivatives of 4-aminobutanamides.
AID129175Anticonvulsant response in mouse was measured by maximal electroshock seizure (MES) test; No protection up to 1000 mg/kg1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Triazolines. 14. 1,2,3-Triazolines and triazoles, a new class of anticonvulsants. Drug design and structure-activity relationships.
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID286843Anticonvulsant activity in Swiss Albino mouse at 300 mg/kg, ip after 0.5 hr by scSTY test2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Discovery of 4-aminobutyric acid derivatives possessing anticonvulsant and antinociceptive activities: a hybrid pharmacophore approach.
AID1864057Cytotoxicity against human HepG2 cells assessed as cell viability at 100 uM measured for 72 hrs
AID227699Virtual screen for compounds with anticonvulsant activity2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
AID1269469Anticonvulsant activity against ip dosed Swiss mouse seizure model assessed as protection at 0.25 hrs by 6 Hz psychomotor seizure test2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
New hybrid molecules with anticonvulsant and antinociceptive activity derived from 3-methyl- or 3,3-dimethyl-1-[1-oxo-1-(4-phenylpiperazin-1-yl)propan-2-yl]pyrrolidine-2,5-diones.
AID226512Protective Index (PI) determined as the ratio of toxic dose (TD50) and effective dose (ED50 (PTZ))1997Journal of medicinal chemistry, Jan-03, Volume: 40, Issue:1
Synthesis and anticonvulsant activities of 3,3-dialkyl- and 3-alkyl-3-benzyl-2-piperidinones (delta-valerolactams) and hexahydro-2H-azepin-2-ones (epsilon-caprolactams).
AID113640ED50 was evaluated from scMET test in mice by delivering intraperitoneally and the value was determined at peak time effect or peak neurologic effect.1991Journal of medicinal chemistry, Jun, Volume: 34, Issue:6
Synthesis and anticonvulsant activity of 2-iminohydantoins.
AID1161059Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against maximal electroshock-induced seizures2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Novel fluorinated pyrrolo[1,2-a]pyrazine-2,6-dione derivatives: synthesis and anticonvulsant evaluation in animal models of epilepsy.
AID1304291Acute neurotoxicity in albino Swiss mouse pretreated for 2 hrs by rotorod test2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Design, synthesis and anticonvulsant activity of new hybrid compounds derived from N-phenyl-2-(2,5-dioxopyrrolidin-1-yl)-propanamides and -butanamides.
AID1183239Anticonvulsant activity in albino Wistar rat assessed as protection against subcutaneous pentylenetetrazol-induced seizures at 50 mg/kg, po at 1 hr2014European journal of medicinal chemistry, Sep-12, Volume: 84Design and synthesis of new of 3-(benzo[d]isoxazol-3-yl)-1-substituted pyrrolidine-2, 5-dione derivatives as anticonvulsants.
AID1720893Protective index, ratio of TD50 for neurotoxicity in KunMing mouse to ED50 for anticonvulsant activity in KunMing mouse assessed as protection against pentylenetetrazole-induced seizure2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants.
AID489796Neurotoxicity in ip dosed Swiss albino mouse assessed as impair in motor coordination at 300 mg/kg, ip after 0.5 hrs by rotarod test2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Combating oxidative stress in epilepsy: design, synthesis, quantum chemical studies and anticonvulsant evaluation of 1-(substituted benzylidene/ethylidene)-4-(naphthalen-1-yl)semicarbazides.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID487180Anticonvulsant activity in ip dosed Albino mouse assessed as protection against scPTZ-induced seizure after 0.5 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis, anticonvulsant and toxicity screening of newer pyrimidine semicarbazone derivatives.
AID1285352Neurotoxicity in CD1 albino mouse assessed as acute motor impairment at 300 mg/kg, ip after 4 hrs by rotarod test2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Synthesis, and anticonvulsant activity of new amides derived from 3-methyl- or 3-ethyl-3-methyl-2,5-dioxo-pyrrolidin-1-yl-acetic acids.
AID121863Neurologic toxicity activity was determined by rotarod toxicity test (Phase II Pharmacological Evaluation)1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Functionalized DL-amino acid derivatives. Potent new agents for the treatment of epilepsy.
AID767978Antimutagenic activity in Vibrio harveyi BB7M assessed as inhibition of 4-nitroquinoline-N-oxide-induced mutation2013European journal of medicinal chemistry, Aug, Volume: 66Synthesis and biological properties of new N-Mannich bases derived from 3-methyl-3-phenyl- and 3,3-dimethyl-succinimides. Part V.
AID779011Anticonvulsant activity in po dosed albino Sprague-Dawley rat assessed as protection against subcutaneous pentylenetetrazole-induced convulsion2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Design, synthesis and anticonvulsant properties of new N-Mannich bases derived from 3-phenylpyrrolidine-2,5-diones.
AID626716Neurotoxicity in ip dosed albino Carworth Farms No.1 mouse assessed as motor impairment after 0.25 hrs by rotarod test2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and anticonvulsant activity of novel 2,6-diketopiperazine derivatives. Part 1: perhydropyrrole[1,2-a]pyrazines.
AID637063Anticonvulsant activity in Kunming mouse assessed as protection against maximal electroshock-induced seizure at 300 mg/kg, ip after 0.5 hrs2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and anticonvulsant activity of 1-(8-(benzyloxy)quinolin-2-yl)-6-substituted-4,6-diazaspiro[2,4]heptane-5,7-diones.
AID1432538Anticonvulsant in ip dosed CD1 mouse assessed as time to peak effect2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Synthesis and evaluation of anticonvulsant properties of new N-Mannich bases derived from pyrrolidine-2,5-dione and its 3-methyl-, 3-isopropyl, and 3-benzhydryl analogs.
AID477738Anticonvulsant activity in Swiss albino mouse assessed as inhibition of PTZ-induced motor impairment at 300 mg/kg, ip after 0.5 hrs2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening.
AID382209Anticonvulsant activity in ip dosed CF1 albino mouse assessed as inhibition of maximal electroshock-induced electrical stimulus at 300 mg/kg after 0.5 hr2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Design, synthesis, and anticonvulsant activity of N-phenylamino derivatives of 3,3-dialkyl-pyrrolidine-2,5-diones and hexahydro-isoindole-1,3-diones.
AID1544805Neurotoxicity in ip dosed albino mouse assessed as motor impairment measured at 0.5 hrs by rotarod test2019Bioorganic & medicinal chemistry letters, 07-15, Volume: 29, Issue:14
Novel benzothiazole hydrazine carboxamide hybrid scaffolds as potential in vitro GABA AT enzyme inhibitors: Synthesis, molecular docking and antiepileptic evaluation.
AID1304289Anticonvulsant activity in albino Swiss mouse measured after 30 mins by subcutaneous pentylenetetrazole seizure test2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Design, synthesis and anticonvulsant activity of new hybrid compounds derived from N-phenyl-2-(2,5-dioxopyrrolidin-1-yl)-propanamides and -butanamides.
AID1173470Anticonvulsant activity against ip dosed CF1 albino mouse seizure model after 4 hrs by 6 Hz psychomotor seizure test2014Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23
Seizure prevention by the naturally occurring phenols, carvacrol and thymol in a partial seizure-psychomotor model.
AID121861Median toxic dose was evaluated by Maximal electroshock seizure test and subcutaneous pentylenetetrazole seizure test through intraperitoneal administration1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Synthesis and evaluation of N-(phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents.
AID122455Time to peak effect in mice was evaluated by Maximal electroshock seizure (MES) test in hours by oral administration1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Synthesis and evaluation of N-(phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents.
AID287121Anticonvulsant activity against subcutaneous pentylenetetrazole-induced seizure in Albino CF1 mouse at 300 mg/kg, ip after 4 hrs2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
Design and synthesis of anticonvulsants from a combined phthalimide-GABA-anilide and hydrazone pharmacophore.
AID545520Anticonvulsant activity in ip dosed mouse assessed as inhibition of maximum electric shock-induced hind limb tonic extension after 4 hrs2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis and anticonvulsant activity of N-3-arylamide substituted 5,5-cyclopropanespirohydantoin derivatives.
AID1742414Protection index, ratio of TD50 for neurotoxicity in ip dosed Kunming mouse to ED50 for anticonvulsant activity in ip dosed ScPTZ-induced Kunming mouse
AID489788Anticonvulsant activity against maximal electroshock-induced seizures in Swiss albino mouse at 300 mg/kg, ip after 0.5 hrs2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Combating oxidative stress in epilepsy: design, synthesis, quantum chemical studies and anticonvulsant evaluation of 1-(substituted benzylidene/ethylidene)-4-(naphthalen-1-yl)semicarbazides.
AID1065317Protective index, ratio of TD50 for neurotoxicity to ED50 for protection against 6 Hz electroshock-induced seizure in albino mouse after 1 hr2013European journal of medicinal chemistry, Sep, Volume: 67Design, synthesis and anticonvulsant evaluation of N-(benzo[d]thiazol-2-ylcarbamoyl)-2-methyl-4-oxoquinazoline-3(4H)-carbothioamide derivatives: a hybrid pharmacophore approach.
AID1264985Neurotoxicity in Swiss albino mouse assessed as inability of animal to maintain equilibrium on rod at 300 mg/kg, ip after 4 hrs by rotarod test2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis of 2,6-dicarbethoxy-3,5-diaryltetrahydro-1,4-thiazine-1,1-dioxide derivatives as potent anticonvulsant agents.
AID1135317Neurotoxicity in ip dosed albino CD-1 mouse assessed as time to peak central activity by rotarod test1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
3,4-Methylenedioxyphenyl-, isopropylidenedioxyphenyl-, and benzyl-substituted chiral 2-aminosuccinimides and 3-aminopyrrolidines. Stereoselective investigations of potential anti-parkinsonian, antipsychotic, and anticonvulsant activities.
AID657397Neurotoxicity in Swiss albino mouse assessed as motor impairment at 300 mg/kg, ip after 0.5 hrs by rotorod test2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Design, synthesis and anticonvulsant activities of novel 1-(substituted/unsubstituted benzylidene)-4-(4-(6,8-dibromo-2-(methyl/phenyl)-4-oxoquinazolin-3(4H)-yl)phenyl) semicarbazide derivatives.
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1161063Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against maximal electroshock-induced seizures measured as time to peak effect2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Novel fluorinated pyrrolo[1,2-a]pyrazine-2,6-dione derivatives: synthesis and anticonvulsant evaluation in animal models of epilepsy.
AID779031Anticonvulsant activity in albino CF1 mouse assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip measured after 0.5 hr2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Design, synthesis and anticonvulsant properties of new N-Mannich bases derived from 3-phenylpyrrolidine-2,5-diones.
AID305065Anticonvulsant activity against pentylenetetrazole-induced seizures in Albino mouse at 300 mg/kg, ip after 0.5 hrs2007Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1
Synthesis and anticonvulsant activity of sulfonamide derivatives-hydrophobic domain.
AID212342Neurotoxicity was evaluated by a rotarod test1997Journal of medicinal chemistry, Jan-03, Volume: 40, Issue:1
Synthesis and anticonvulsant activities of 3,3-dialkyl- and 3-alkyl-3-benzyl-2-piperidinones (delta-valerolactams) and hexahydro-2H-azepin-2-ones (epsilon-caprolactams).
AID287135Neurotoxicity in Albino CF1 mouse at 300 mg/kg, ip after 4 hrs by Rotarod test2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
Design and synthesis of anticonvulsants from a combined phthalimide-GABA-anilide and hydrazone pharmacophore.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID113782Anticonvulsant activity in mice against pentylenetetrazole (PTZ) induced clonic seizures1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
3,3-Dialkyl- and 3-alkyl-3-benzyl-substituted 2-pyrrolidinones: a new class of anticonvulsant agents.
AID364293Anticonvulsant activity in mouse at 300 mg/kg, ip after 4 hrs by scPTZ test2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
CNS depressant and anticonvulsant activities of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones.
AID395118Anticonvulsant activity against pentylenetetrazole-induced seizures in Wistar albino rat at 50 mg/kg, po after 0.25 hrs by scPTZ test2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis of some novel N4-(naphtha[1,2-d]thiazol-2-yl)semicarbazides as potential anticonvulsants.
AID286847Anticonvulsant activity in Swiss Albino mouse at 300 mg/kg, ip after 4 hrs by scSTY test2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Discovery of 4-aminobutyric acid derivatives possessing anticonvulsant and antinociceptive activities: a hybrid pharmacophore approach.
AID394941Anticonvulsant activity against pentylenetetrazole-induced seizures in Swiss albino mouse at 300 mg/kg, ip after 4 hrs by scPTZ test2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis of some novel N4-(naphtha[1,2-d]thiazol-2-yl)semicarbazides as potential anticonvulsants.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1246358Anticonvulsant activity in albino CD-1 mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizure at 30 to 300 mg/kg, ip measured after 2.0 hrs2015European journal of medicinal chemistry, Sep-18, Volume: 102Design, synthesis and biological activity of new amides derived from 3-methyl-3-phenyl-2,5-dioxo-pyrrolidin-1-yl-acetic acid.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID290721Anticonvulsant activity against maximal-electroshock-induced seizure in mouse at 300 mg/kg, ip after 0.5 hrs2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Synthesis and anticonvulsant activity of 4-(2-(2,6-dimethylphenylamino)-2-oxoethylamino)-N-(substituted)butanamides: a pharmacophoric hybrid approach.
AID657389Anticonvulsant activity in Swiss albino mouse assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip after 0.5 hrs2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Design, synthesis and anticonvulsant activities of novel 1-(substituted/unsubstituted benzylidene)-4-(4-(6,8-dibromo-2-(methyl/phenyl)-4-oxoquinazolin-3(4H)-yl)phenyl) semicarbazide derivatives.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID140326Time of peak effect toxicity against maximal electroshock induced seizures1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Synthesis and anticonvulsant activity of 2-benzylglutarimides.
AID1195113Anticonvulsant activity in intraperitoneally dosed Albino Swiss CD1 mouse by maximal electroshock test2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
Design, synthesis and biological evaluation of new hybrid anticonvulsants derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide derivatives.
AID727852Antiepileptic activity in Wistar rat assessed as protection against scSTY-induced seizures at 300 mg/kg, ip measured after 4 hrs2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Novel limonene and citral based 2,5-disubstituted-1,3,4-oxadiazoles: a natural product coupled approach to semicarbazones for antiepileptic activity.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1378591Anticonvulsant activity in ip dosed CF1 mouse assessed as protection against 44 mA current-induced seizure after 15 mins by 6 Hz psychomotor test2017Journal of natural products, 08-25, Volume: 80, Issue:8
Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.
AID767981Induction of mutagenecity in Vibrio harveyi BB7XM2013European journal of medicinal chemistry, Aug, Volume: 66Synthesis and biological properties of new N-Mannich bases derived from 3-methyl-3-phenyl- and 3,3-dimethyl-succinimides. Part V.
AID1133867Anticonvulsant activity in mouse assessed as protection against metrazole-induced seizures at 300 mg/kg, ip after 30 mins by subcutaneous pentylenetetrazole seizure threshold test1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Potential long-acting anticonvulsants. 1; Synthesis and activity of succinimides containing an alkylating group at the 2 position.
AID511973Neurotoxicity in Kunming rat assessed as minimum motor impairment at 30 mg/kg, po after 1 hr by rotarod test2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis and anticonvulsant activity of new 6-methyl-1-substituted-4,6-diazaspiro[2.4]heptane-5,7-diones.
AID225292Effective dose was measured in rat by subcutaneous pentylenetetrazole method by ip administration; 111-1511993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis and CLOGP correlation of imidooxy anticonvulsants.
AID683944Anticonvulsant activity in CF-1 albino mouse assessed as protection from maximal electric shock-induced seizures at 300 mg/kg, ip measured after 4 hrs2012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Synthesis and anticonvulsant activity of new N-Mannich bases derived from 3-(2-fluorophenyl)- and 3-(2-bromophenyl)-pyrrolidine-2,5-diones. Part II.
AID168748Median Effective dose was evaluated by Subcutaneous pentylenetetrazole seizure test in Rats by oral administration1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Synthesis and evaluation of N-(phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents.
AID1143166Anticonvulsant activity in ip dosed Swiss albino mouse assessed as protection against pentylenetetrazole-induced seizures after 4 hrs2014European journal of medicinal chemistry, Jun-10, Volume: 80Anticonvulsant evaluation of clubbed indole-1,2,4-triazine derivatives: a synthetic approach.
AID286856Neurotoxicity in Swiss Albino mouse at 300 mg/kg, ip after 4 hrs by rotarod test2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Discovery of 4-aminobutyric acid derivatives possessing anticonvulsant and antinociceptive activities: a hybrid pharmacophore approach.
AID113976Anticonvulsant activity was determined by subcutaneous Metrazol-induced convulsions (sc MET)(Phase V Pharmacological Evaluation)1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Functionalized DL-amino acid derivatives. Potent new agents for the treatment of epilepsy.
AID1133863Anticonvulsant activity in ip dosed mouse assessed as protection against maximal electroshock-induced hindlimb tonic extensor component of seizure by MES test1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Potential long-acting anticonvulsants. 1; Synthesis and activity of succinimides containing an alkylating group at the 2 position.
AID113703Inhibition of picrotoxin-induced seizures in mice by ip administration at 250-1000 mg/kg (h= maximum 62.5% protection)1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Synthesis and evaluation of N-(phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents.
AID1161060Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against subcutaneous metrazol-induced seizures2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Novel fluorinated pyrrolo[1,2-a]pyrazine-2,6-dione derivatives: synthesis and anticonvulsant evaluation in animal models of epilepsy.
AID1229797Anticonvulsant activity in ip dosed Swiss mouse assessed as protection against seizures measured at 0.25 hrs of time to peak effect by 6 Hz test by 6 Hz psychomotor seizure test2015Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
Design, synthesis, and anticonvulsant activity of new hybrid compounds derived from 2-(2,5-dioxopyrrolidin-1-yl)propanamides and 2-(2,5-dioxopyrrolidin-1-yl)butanamides.
AID122341Time to peak activity was evaluated by Maximal electroshock seizure test in hours1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Synthesis and evaluation of N-(phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents.
AID637065Anticonvulsant activity in ip dosed Kunming mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizure after 0.5 hrs2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and anticonvulsant activity of 1-(8-(benzyloxy)quinolin-2-yl)-6-substituted-4,6-diazaspiro[2,4]heptane-5,7-diones.
AID1285345Anticonvulsant activity in CD1 albino mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 100 to 300 mg/kg, ip after 0.5 hrs2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Synthesis, and anticonvulsant activity of new amides derived from 3-methyl- or 3-ethyl-3-methyl-2,5-dioxo-pyrrolidin-1-yl-acetic acids.
AID511893Neurotoxicity in Kunming rat assessed as minimum motor impairment at 30 mg/kg, po after 0.25 hrs by rotarod test2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis and anticonvulsant activity of new 6-methyl-1-substituted-4,6-diazaspiro[2.4]heptane-5,7-diones.
AID113777Anticonvulsant activity expressed as dose at which 50% of the mice were protected from clonic seizures induced by pentylenetetrazole (85 mg/Kg)1997Journal of medicinal chemistry, Jan-03, Volume: 40, Issue:1
Synthesis and anticonvulsant activities of 3,3-dialkyl- and 3-alkyl-3-benzyl-2-piperidinones (delta-valerolactams) and hexahydro-2H-azepin-2-ones (epsilon-caprolactams).
AID1133873Neurotoxicity in ip dosed mouse by rotarod test1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Potential long-acting anticonvulsants. 1; Synthesis and activity of succinimides containing an alkylating group at the 2 position.
AID132476The compound was tested for anticonvulsant activity against (subcutaneous administered) strychnine induced seizures after intraperitoneal administration; Maximum 62% protection at 250-1000 mg/kg.1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Synthesis and anticonvulsant activity of 2-benzylglutarimides.
AID1183232Neurotoxicity in albino Wistar rat at 300 mg/kg, ip at 0.5 hr by rotorod test2014European journal of medicinal chemistry, Sep-12, Volume: 84Design and synthesis of new of 3-(benzo[d]isoxazol-3-yl)-1-substituted pyrrolidine-2, 5-dione derivatives as anticonvulsants.
AID1452160Anticonvulsant activity in ip dosed Albino Swiss CD-1 mouse assessed as inhibition of pentylenetetrazole-induced seizures administered up to 2 hrs prior to PTZ induction measured at time to peak effect
AID1415357Anticonvulsant activity in mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures by measuring latency time of tonic seizures at 50 mg/kg, ip measured for 30 mins post pentylenetetrazole challenge at 0.5 hrs after compound d2017MedChemComm, Jan-01, Volume: 8, Issue:1
Design, synthesis and anticonvulsant-analgesic activity of new
AID382384Anticonvulsant activity in mouse assessed as inhibition of maximal electroshock-induced seizures at 300 mg/kg, ip after 4 hrs2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Synthesis and CNS depressant activity of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones.
AID489285Anticonvulsant activity against maximal electroshock-induced seizures in Swiss albino mouse at 300 mg/kg, ip after 4 hrs2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Novel semicarbazones based 2,5-disubstituted-1,3,4-oxadiazoles: one more step towards establishing four binding site pharmacophoric model hypothesis for anticonvulsant activity.
AID1742412Neurotoxicity in ip dosed Kunming mouse measured after 30 mins by rotarod test
AID364290Anticonvulsant activity in ip dosed mouse after 0.5 hrs by scPTZ test2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
CNS depressant and anticonvulsant activities of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones.
AID290730Anticonvulsant activity against subcutaneous picrotoxin-induced seizure in mouse at 300 mg/kg, ip after 4 hrs2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Synthesis and anticonvulsant activity of 4-(2-(2,6-dimethylphenylamino)-2-oxoethylamino)-N-(substituted)butanamides: a pharmacophoric hybrid approach.
AID286850Anticonvulsant activity in Swiss Albino mouse at 300 mg/kg, ip after 0.5 hr by scPIC test2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Discovery of 4-aminobutyric acid derivatives possessing anticonvulsant and antinociceptive activities: a hybrid pharmacophore approach.
AID629165Antiepileptic activity in Swiss albino mouse assessed as protection against maximum electric shock-induced seizure at 300 mg/kg, ip after 4 hrs2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Design, synthesis and antiepileptic properties of novel 1-(substituted benzylidene)-3-(1-(morpholino/piperidino methyl)-2,3-dioxoindolin-5-yl)urea derivatives.
AID1183238Anticonvulsant activity in albino Wistar rat assessed as protection against subcutaneous pentylenetetrazol-induced seizures at 50 mg/kg, po at 0.5 hr2014European journal of medicinal chemistry, Sep-12, Volume: 84Design and synthesis of new of 3-(benzo[d]isoxazol-3-yl)-1-substituted pyrrolidine-2, 5-dione derivatives as anticonvulsants.
AID121858Median Effective dose was evaluated by Neurologic toxicity (rotarod test) in mice by oral administration1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Synthesis and evaluation of N-(phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents.
AID1415354Anticonvulsant activity in mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures by measuring latency time of tonic seizures at 100 mg/kg, ip measured for 30 mins post pentylenetetrazole challenge at 0.5 hrs after compound 2017MedChemComm, Jan-01, Volume: 8, Issue:1
Design, synthesis and anticonvulsant-analgesic activity of new
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID396623Anticonvulsant activity in Swiss albino mouse assessed as inhibition of subcutaneous strychnine-induced seizures at 300 mg/kg, ip administered 30 mins before STY challenge measured after 0.5 hrs post STY challenge2008European journal of medicinal chemistry, Dec, Volume: 43, Issue:12
Newer GABA derivatives for the treatment of epilepsy including febrile seizures: a bioisosteric approach.
AID111833Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 20 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID129171Anticonvulsant activity in mice, measured by subcutaneous pentylenetetrazole seizure (scMet) test.1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Triazolines. 14. 1,2,3-Triazolines and triazoles, a new class of anticonvulsants. Drug design and structure-activity relationships.
AID364305Neurotoxicity in mouse assessed as minimal motor impairment at 300 mg/kg, ip after 4 hrs by rotarod test2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
CNS depressant and anticonvulsant activities of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones.
AID287125Anticonvulsant activity against subcutaneous strychnine-induced seizure in Albino CF1 mouse at 300 mg/kg, ip after 4 hrs2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
Design and synthesis of anticonvulsants from a combined phthalimide-GABA-anilide and hydrazone pharmacophore.
AID1065337Neurotoxicity in albino mouse at 300 mg/kg, ip after 0.5 hrs by rotorod test2013European journal of medicinal chemistry, Sep, Volume: 67Design, synthesis and anticonvulsant evaluation of N-(benzo[d]thiazol-2-ylcarbamoyl)-2-methyl-4-oxoquinazoline-3(4H)-carbothioamide derivatives: a hybrid pharmacophore approach.
AID1135321Anticonvulsant activity in ip dosed albino CD-1 mouse assessed as threshold ratio for pentylenetetrazole-induced tonic-clonic seizures at 0.5 time TD50 measured at time of peak effect relative to saline-treated control1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
3,4-Methylenedioxyphenyl-, isopropylidenedioxyphenyl-, and benzyl-substituted chiral 2-aminosuccinimides and 3-aminopyrrolidines. Stereoselective investigations of potential anti-parkinsonian, antipsychotic, and anticonvulsant activities.
AID1161077Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against 6 Hz current-induced seizures measured as time to peak effect2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Novel fluorinated pyrrolo[1,2-a]pyrazine-2,6-dione derivatives: synthesis and anticonvulsant evaluation in animal models of epilepsy.
AID1065336Neurotoxicity in albino mouse at 300 mg/kg, ip after 4 hrs by rotorod test2013European journal of medicinal chemistry, Sep, Volume: 67Design, synthesis and anticonvulsant evaluation of N-(benzo[d]thiazol-2-ylcarbamoyl)-2-methyl-4-oxoquinazoline-3(4H)-carbothioamide derivatives: a hybrid pharmacophore approach.
AID540232Dose normalised AUC in monkey after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1246366Neurotoxicity in ip dosed albino CD-1 mouse assessed as motor impairment by rotarod test2015European journal of medicinal chemistry, Sep-18, Volume: 102Design, synthesis and biological activity of new amides derived from 3-methyl-3-phenyl-2,5-dioxo-pyrrolidin-1-yl-acetic acid.
AID132649The effective dose of compound was tested against maximal electroshock induced seizures after oral administration in mice.1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Synthesis and anticonvulsant activity of 2-benzylglutarimides.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1246357Anticonvulsant activity in albino CD-1 mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizure at 30 to 300 mg/kg, ip measured after 0.5 hrs2015European journal of medicinal chemistry, Sep-18, Volume: 102Design, synthesis and biological activity of new amides derived from 3-methyl-3-phenyl-2,5-dioxo-pyrrolidin-1-yl-acetic acid.
AID1183245Anticonvulsant activity in po dosed albino Wistar rat assessed as protection against subcutaneous pentylenetetrazol-induced seizures at 2 hrs2014European journal of medicinal chemistry, Sep-12, Volume: 84Design and synthesis of new of 3-(benzo[d]isoxazol-3-yl)-1-substituted pyrrolidine-2, 5-dione derivatives as anticonvulsants.
AID779021Neurotoxicity in albino CF1 mouse assessed as minimum motor impairment at 300 mg/kg, ip measured after 0.5 hr by rotorod test2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Design, synthesis and anticonvulsant properties of new N-Mannich bases derived from 3-phenylpyrrolidine-2,5-diones.
AID113706Inhibition of seizures induced in mice by a convulsant dose of strychnine through ip administration1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Synthesis and evaluation of N-(phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents.
AID1246356Anticonvulsant activity in albino CD-1 mouse assessed as protection against maximal electroshock-induced seizure at 30 to 300 mg/kg, ip measured after 2.0 hrs2015European journal of medicinal chemistry, Sep-18, Volume: 102Design, synthesis and biological activity of new amides derived from 3-methyl-3-phenyl-2,5-dioxo-pyrrolidin-1-yl-acetic acid.
AID1742411Anticonvulsant activity in ip dosed Kunming mouse assessed as reduction in ScPTZ-induced seizure measured after 30 mins
AID1452171Protection index, ratio of TD50 for neurotoxicity in ip dosed Albino Swiss CD-1 mouse to ED50 for ip dosed Albino Swiss CD-1 mouse model of 6 Hz-induced siezures
AID113779Anticonvulsant activity expressed as dose at which 50% of the mice were protected from tonic hindlimb seizures induced by maximal electroshock (MES)1997Journal of medicinal chemistry, Jan-03, Volume: 40, Issue:1
Synthesis and anticonvulsant activities of 3,3-dialkyl- and 3-alkyl-3-benzyl-2-piperidinones (delta-valerolactams) and hexahydro-2H-azepin-2-ones (epsilon-caprolactams).
AID1196897Anticonvulsant activity in Kunming mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 300 mg/kg, ip after 4 hrs2015European journal of medicinal chemistry, Mar-06, Volume: 92Design, synthesis and pharmacological evaluation of novel N-(2-(1, 1-dimethyl-5, 7-dioxo-4, 6-diazaspiro[2.4]heptan-6-yl)ethyl) sulfonamide derivatives as potential anticonvulsant agents.
AID1246362Anticonvulsant activity in ip dosed albino CD-1 mouse assessed as protection against maximal electroshock-induced seizure2015European journal of medicinal chemistry, Sep-18, Volume: 102Design, synthesis and biological activity of new amides derived from 3-methyl-3-phenyl-2,5-dioxo-pyrrolidin-1-yl-acetic acid.
AID382195Anticonvulsant activity in Sprague-Dawley rat assessed as protection against seizure at 50 mg/kg, po after 4 hrs by subcutaneous pentylenetetrazole test2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Design, synthesis, and anticonvulsant activity of N-phenylamino derivatives of 3,3-dialkyl-pyrrolidine-2,5-diones and hexahydro-isoindole-1,3-diones.
AID779032Anticonvulsant activity in albino CF1 mouse assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip measured after 4 hrs2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Design, synthesis and anticonvulsant properties of new N-Mannich bases derived from 3-phenylpyrrolidine-2,5-diones.
AID489790Anticonvulsant activity against maximal electroshock-induced seizures in Swiss albino mouse at 300 mg/kg, ip after 4 hrs2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Combating oxidative stress in epilepsy: design, synthesis, quantum chemical studies and anticonvulsant evaluation of 1-(substituted benzylidene/ethylidene)-4-(naphthalen-1-yl)semicarbazides.
AID128044Anticonvulsant activity against picrotoxin-induced clonic seizures in mice at 3.2 mg/kg sc1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
2-Phenyl-3H-imidazo[4,5-b]pyridine-3-acetamides as non-benzodiazepine anticonvulsants and anxiolytics.
AID1133869Anticonvulsant activity in mouse assessed as protection against metrazole-induced seizures at 300 mg/kg, ip after 4 hrs by subcutaneous pentylenetetrazole seizure threshold test1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Potential long-acting anticonvulsants. 1; Synthesis and activity of succinimides containing an alkylating group at the 2 position.
AID657391Anticonvulsant activity in Swiss albino mouse assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip after 4 hrs2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Design, synthesis and anticonvulsant activities of novel 1-(substituted/unsubstituted benzylidene)-4-(4-(6,8-dibromo-2-(methyl/phenyl)-4-oxoquinazolin-3(4H)-yl)phenyl) semicarbazide derivatives.
AID666667Anticonvulsant activity in Kunming mouse assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip measured after 4 hrs2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and anticonvulsant activity of ethyl 1-(2-arylhydrazinecarboxamido)-2,2-dimethylcyclopropanecarboxylate derivatives.
AID1711722Neurotoxicity activity in ip dosed mouse assessed as induction of motor impairment by rotarod test2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Synthesis and evaluation of anticonvulsant properties of new N-Mannich bases derived from 3-(1-phenylethyl)- and 3-benzyl-pyrrolidine-2,5-dione.
AID226706Protective index which is the ratio of TD50 to ED50 of against subcutaneous pentylenetetrazole test1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and anticonvulsant activity of imidooxy derivatives.
AID1452162Anticonvulsant activity in Albino Swiss CD-1 mouse assessed as protection against maximal electroshock-induced seizures by measuring time to peak effect at 100 mg/kg, ip pretreated up to 2 hrs followed by 50 Hz current induction for 2 secs
AID628727Anticonvulsant activity in ip dosed CF1 albino mouse assessed as protection against subcutaneous pentylenetetrazole-induced after 0.5 hrs2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and anticonvulsant properties of new acetamide derivatives of phthalimide, and its saturated cyclohexane and norbornene analogs.
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID382368Anticonvulsant activity in ip dosed mouse assessed as inhibition of pentylenetetrazole-induced seizure after 0.5 hrs2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Synthesis and CNS depressant activity of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones.
AID1863985Toxicity in CD-1 seizure mouse model assessed as effect on motor coordination administered ip measured after 0.25 hrs for 3 mins by rotarod test
AID626715Anticonvulsant activity in ip dosed albino Carworth Farms No.1 mouse assessed as protection against subcutaneous metrazol-induced seizure after 0.25 hrs2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and anticonvulsant activity of novel 2,6-diketopiperazine derivatives. Part 1: perhydropyrrole[1,2-a]pyrazines.
AID1156742Anticonvulsant activity against pentylenetetrazole-induced seizure in albino Swiss (CD-1) mouse assessed as delay in onset of seizures at 100 mg/kg, ip administered 60 mins prior to PTZ challenge2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis, biological evaluation and structure-activity relationship of new GABA uptake inhibitors, derivatives of 4-aminobutanamides.
AID22951Time of peak effect (TPE) for toxicity1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and anticonvulsant activity of imidooxy derivatives.
AID396624Anticonvulsant activity in Swiss albino mouse assessed as inhibition of subcutaneous strychnine-induced seizures at 300 mg/kg, ip administered 30 mins before STY challenge measured after 4 hrs post STY challenge2008European journal of medicinal chemistry, Dec, Volume: 43, Issue:12
Newer GABA derivatives for the treatment of epilepsy including febrile seizures: a bioisosteric approach.
AID623225Anticonvulsant activity in ip dosed CF1 albino mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures after 4 hrs2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Synthesis and anticonvulsant activity of new N-Mannich bases derived from 5-cyclopropyl-5-phenyl- and 5-cyclopropyl-5-(4-chlorophenyl)-imidazolidine-2,4-diones.
AID287133Neurotoxicity in Albino CF1 mouse at 300 mg/kg, ip after 0.5 hrs by Rotarod test2007European journal of medicinal chemistry, Feb, Volume: 42, Issue:2
Design and synthesis of anticonvulsants from a combined phthalimide-GABA-anilide and hydrazone pharmacophore.
AID471590Anticonvulsant activity against electric stimulation-induced pharmacoresistant limbic epilepsy in ip dosed Sprague-Dawley rat kindling model assessed as reduction of seizure severity and excitability administered 15 mins after last electric stimulation me2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Novel, broad-spectrum anticonvulsants containing a sulfamide group: advancement of N-((benzo[b]thien-3-yl)methyl)sulfamide (JNJ-26990990) into human clinical studies.
AID1191603Anticonvulsant activity in Swiss albino mouse assessed as reduction in electrical stimulus-induced seizures at 300 mg/kg, ip after 4 hrs by maximal electroshock seizure test2015Bioorganic & medicinal chemistry letters, Mar-01, Volume: 25, Issue:5
Design, synthesis and pharmacological evaluation of N-[4-(4-(alkyl/aryl/heteroaryl)-piperazin-1-yl)-phenyl]-carbamic acid ethyl ester derivatives as novel anticonvulsant agents.
AID1544808Anticonvulsant activity in ip dosed albino mouse model of subcutaneous pentylenetetrazole-induced seizure assessed as failure to observe even a single episode of clonic spasms for at least 5 secs pretreated for 4 hrs followed by pentylenetetrazole inducti2019Bioorganic & medicinal chemistry letters, 07-15, Volume: 29, Issue:14
Novel benzothiazole hydrazine carboxamide hybrid scaffolds as potential in vitro GABA AT enzyme inhibitors: Synthesis, molecular docking and antiepileptic evaluation.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID767982Induction of mutagenecity in Vibrio harveyi BB7M2013European journal of medicinal chemistry, Aug, Volume: 66Synthesis and biological properties of new N-Mannich bases derived from 3-methyl-3-phenyl- and 3,3-dimethyl-succinimides. Part V.
AID382386Anticonvulsant activity in mouse assessed as inhibition of pentylenetetrazole-induced seizure at 300 mg/kg, ip after 4 hrs2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Synthesis and CNS depressant activity of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones.
AID489289Neurotoxicity in Swiss albino mouse at 300 mg/kg, ip after 4 hrs2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Novel semicarbazones based 2,5-disubstituted-1,3,4-oxadiazoles: one more step towards establishing four binding site pharmacophoric model hypothesis for anticonvulsant activity.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID114420Median hypnotic dose was evaluated by loss of righting reflex1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Synthesis and evaluation of N-(phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID382383Anticonvulsant activity in mouse assessed as inhibition of maximal electroshock-induced seizures at 300 mg/kg, ip after 0.5 hrs2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Synthesis and CNS depressant activity of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones.
AID113979Anticonvulsant activity was determined by subcutaneous Metrazol-induced convulsions seizure test (Phase IV Pharmacological Evaluation)1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Functionalized DL-amino acid derivatives. Potent new agents for the treatment of epilepsy.
AID487193Neurotoxicity in Albino mouse assessed as minimal motor impairment at 300 mg/kg, ip after 4 hrs by rotarod test2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis, anticonvulsant and toxicity screening of newer pyrimidine semicarbazone derivatives.
AID1452165Anticonvulsant activity in Albino Swiss CD-1 mouse assessed as inhibition of pentylenetetrazole-induced seizures by measuring time to peak effect at 100 mg/kg, ip administered up to 2 hrs prior to PTZ induction measured for 30 mins
AID1195112Anticonvulsant activity in intraperitoneally dosed Albino Swiss CD1 mouse assessed as time to peak effect after 2 hrs by subcutaneous pentylenetetrazole test2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
Design, synthesis and biological evaluation of new hybrid anticonvulsants derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide derivatives.
AID623090Anticonvulsant activity in po dosed Sprague-Dawley albino rat assessed as protection against maximal electroshock-induced seizures2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Synthesis and anticonvulsant activity of new N-Mannich bases derived from 5-cyclopropyl-5-phenyl- and 5-cyclopropyl-5-(4-chlorophenyl)-imidazolidine-2,4-diones.
AID1196896Anticonvulsant activity in Kunming mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 100 mg/kg, ip after 0.5 hrs2015European journal of medicinal chemistry, Mar-06, Volume: 92Design, synthesis and pharmacological evaluation of novel N-(2-(1, 1-dimethyl-5, 7-dioxo-4, 6-diazaspiro[2.4]heptan-6-yl)ethyl) sulfonamide derivatives as potential anticonvulsant agents.
AID1196899Neurotoxicity in Kunming mouse assessed as motor impairment at 300 mg/kg, ip after 4 hrs by standardized rotarod test2015European journal of medicinal chemistry, Mar-06, Volume: 92Design, synthesis and pharmacological evaluation of novel N-(2-(1, 1-dimethyl-5, 7-dioxo-4, 6-diazaspiro[2.4]heptan-6-yl)ethyl) sulfonamide derivatives as potential anticonvulsant agents.
AID231257Protective index (PI),anticonvulsant activity, ratio of TD50/ED50 value in scMet test1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Triazolines. 14. 1,2,3-Triazolines and triazoles, a new class of anticonvulsants. Drug design and structure-activity relationships.
AID1058304Anticonvulsant activity in ip dosed Sprague-Dawley rat hippocampal kindling model assessed as suppression of seizure activity treated 15 for mins post suprathreshold-stimulation2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Novel, broad-spectrum anticonvulsants containing a sulfamide group: pharmacological properties of (S)-N-[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide (JNJ-26489112).
AID1133862Anticonvulsant activity in mouse assessed as protection against maximal electroshock-induced hindlimb tonic extensor component of seizure at 300 mg/kg, ip after 4 hrs by MES test1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Potential long-acting anticonvulsants. 1; Synthesis and activity of succinimides containing an alkylating group at the 2 position.
AID305067Anticonvulsant activity against pentylenetetrazole-induced seizures in Albino mouse at 300 mg/kg, ip after 4 hrs2007Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1
Synthesis and anticonvulsant activity of sulfonamide derivatives-hydrophobic domain.
AID1544804Neurotoxicity in ip dosed albino mouse assessed as motor impairment measured at 4 hrs by rotarod test2019Bioorganic & medicinal chemistry letters, 07-15, Volume: 29, Issue:14
Novel benzothiazole hydrazine carboxamide hybrid scaffolds as potential in vitro GABA AT enzyme inhibitors: Synthesis, molecular docking and antiepileptic evaluation.
AID122458Time to peak effect in mice was evaluated by Subcutaneous pentylenetetrazole seizure test in hours by oral administration1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Synthesis and evaluation of N-(phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents.
AID127821The effective dose of compound was tested against maximal electroshock induced seizures after intraperitoneal administration.1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Synthesis and anticonvulsant activity of 2-benzylglutarimides.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1864027Binding affinity to human Cav3.2 at 100 uM by Qpatch electrophysiological assay
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1269440Protective index, ratio of TD50 for neurotoxicity in ip dosed Swiss mouse to ED50 for anticonvulsant activity in ip dosed scPTZ Swiss mouse model at 0.25 hrs2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
New hybrid molecules with anticonvulsant and antinociceptive activity derived from 3-methyl- or 3,3-dimethyl-1-[1-oxo-1-(4-phenylpiperazin-1-yl)propan-2-yl]pyrrolidine-2,5-diones.
AID121864Neurologic toxicity activity was determined by rotarod toxicity test (Phase IV Pharmacological Evaluation)1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Functionalized DL-amino acid derivatives. Potent new agents for the treatment of epilepsy.
AID1246360Neurotoxicity in albino CD-1 mouse assessed as motor impairment at 30 to 300 mg/kg mg/kg, ip measured after 2 hrs by rotarod test2015European journal of medicinal chemistry, Sep-18, Volume: 102Design, synthesis and biological activity of new amides derived from 3-methyl-3-phenyl-2,5-dioxo-pyrrolidin-1-yl-acetic acid.
AID1161071Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against 6 Hz current-induced seizures2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Novel fluorinated pyrrolo[1,2-a]pyrazine-2,6-dione derivatives: synthesis and anticonvulsant evaluation in animal models of epilepsy.
AID540233Dose normalised AUC in human after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID1183246Neurotoxicity in po dosed albino Wistar rat at 2 hrs by rotorod test2014European journal of medicinal chemistry, Sep-12, Volume: 84Design and synthesis of new of 3-(benzo[d]isoxazol-3-yl)-1-substituted pyrrolidine-2, 5-dione derivatives as anticonvulsants.
AID516041Anticonvulsant activity in Sprague-Dawley rat assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 50 mg/kg po after 4 hrs2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Design, synthesis, and anticonvulsant activity of new N-Mannich bases derived from spirosuccinimides and spirohydantoins.
AID629161Neurotoxicity in ip dosed Swiss albino mouse assessed as minimal motor impairment at 300 mg/kg, ip after 4 hrs by rotarod test2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Design, synthesis and antiepileptic properties of novel 1-(substituted benzylidene)-3-(1-(morpholino/piperidino methyl)-2,3-dioxoindolin-5-yl)urea derivatives.
AID779027Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against subcutaneous pentylenetetrazole-induced convulsion in half or more animals measured after 0.5 hr2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Design, synthesis and anticonvulsant properties of new N-Mannich bases derived from 3-phenylpyrrolidine-2,5-diones.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1183224Anticonvulsant activity in albino Swiss mouse assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip at 0.5 hr2014European journal of medicinal chemistry, Sep-12, Volume: 84Design and synthesis of new of 3-(benzo[d]isoxazol-3-yl)-1-substituted pyrrolidine-2, 5-dione derivatives as anticonvulsants.
AID666669Anticonvulsant activity in Kunming mouse assessed as protection against subcutaneous pentylenetetrazol-induced clonic seizures at 100 mg/kg, ip measured after 0.5 hrs2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and anticonvulsant activity of ethyl 1-(2-arylhydrazinecarboxamido)-2,2-dimethylcyclopropanecarboxylate derivatives.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID628728Anticonvulsant activity in ip dosed CF1 albino mouse assessed as protection against subcutaneous pentylenetetrazole-induced after 4 hrs2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and anticonvulsant properties of new acetamide derivatives of phthalimide, and its saturated cyclohexane and norbornene analogs.
AID727989Antiepileptic activity in ip dosed Wistar rat assessed as protection against scSTY-induced seizures after 0.5 hrs2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Novel limonene and citral based 2,5-disubstituted-1,3,4-oxadiazoles: a natural product coupled approach to semicarbazones for antiepileptic activity.
AID1285344Anticonvulsant activity in CD1 albino mouse assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip after 4 hrs2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Synthesis, and anticonvulsant activity of new amides derived from 3-methyl- or 3-ethyl-3-methyl-2,5-dioxo-pyrrolidin-1-yl-acetic acids.
AID516024Neurotoxicity in CF1 albino mouse at 300 mg/kg, ip after 0.5 hrs by rotarod test2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Design, synthesis, and anticonvulsant activity of new N-Mannich bases derived from spirosuccinimides and spirohydantoins.
AID382180Anticonvulsant activity in ip dosed CF1 albino mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced electrical stimulus after 4 hrs2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Design, synthesis, and anticonvulsant activity of N-phenylamino derivatives of 3,3-dialkyl-pyrrolidine-2,5-diones and hexahydro-isoindole-1,3-diones.
AID767977Antimutagenic activity in Vibrio harveyi BB7XM assessed as inhibition of 4-nitroquinoline-N-oxide-induced mutation2013European journal of medicinal chemistry, Aug, Volume: 66Synthesis and biological properties of new N-Mannich bases derived from 3-methyl-3-phenyl- and 3,3-dimethyl-succinimides. Part V.
AID1161062Protective index, ratio of TD50 for neurotoxicity in ip dosed albino CF1 mouse to ED50 for anticonvulsant activity in ip dosed MES albino CF1 mouse model2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Novel fluorinated pyrrolo[1,2-a]pyrazine-2,6-dione derivatives: synthesis and anticonvulsant evaluation in animal models of epilepsy.
AID621009Anticonvulsant activity in albino CF1 mouse assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip after 4 hrs2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Synthesis and anticonvulsant activity of new 1-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]pyrrolidine-2,5-diones.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1135318Anticonvulsant activity in ip dosed albino CD-1 mouse assessed as protection from maximal electroshock-induced seizures measured at time of peak effect1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
3,4-Methylenedioxyphenyl-, isopropylidenedioxyphenyl-, and benzyl-substituted chiral 2-aminosuccinimides and 3-aminopyrrolidines. Stereoselective investigations of potential anti-parkinsonian, antipsychotic, and anticonvulsant activities.
AID305059Anticonvulsant activity against maximal electroshock-induced seizure in Albino mouse at 300 mg/kg, ip after 0.5 hrs2007Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1
Synthesis and anticonvulsant activity of sulfonamide derivatives-hydrophobic domain.
AID1432519Anticonvulsant activity in ip dosed albino CD1 mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Synthesis and evaluation of anticonvulsant properties of new N-Mannich bases derived from pyrrolidine-2,5-dione and its 3-methyl-, 3-isopropyl, and 3-benzhydryl analogs.
AID286840Anticonvulsant activity in Swiss Albino mouse at 300 mg/kg, ip after 4 hrs by MES test2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Discovery of 4-aminobutyric acid derivatives possessing anticonvulsant and antinociceptive activities: a hybrid pharmacophore approach.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID545522Anticonvulsant activity in ip dosed mouse assessed as inhibition of PTZ-induced clonic seizure after 4 hrs2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis and anticonvulsant activity of N-3-arylamide substituted 5,5-cyclopropanespirohydantoin derivatives.
AID629166Antiepileptic activity in Swiss albino mouse assessed as protection against maximum electric shock-induced seizure at 300 mg/kg, ip after 0.5 hrs2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Design, synthesis and antiepileptic properties of novel 1-(substituted benzylidene)-3-(1-(morpholino/piperidino methyl)-2,3-dioxoindolin-5-yl)urea derivatives.
AID1246363Anticonvulsant activity in ip dosed albino CD-1 mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizure2015European journal of medicinal chemistry, Sep-18, Volume: 102Design, synthesis and biological activity of new amides derived from 3-methyl-3-phenyl-2,5-dioxo-pyrrolidin-1-yl-acetic acid.
AID516020Anticonvulsant activity in ip dosed CF1 albino mouse assessed as dose required to protect against subcutaneous pentylenetetrazole-induced seizures after 0.5 hrs2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Design, synthesis, and anticonvulsant activity of new N-Mannich bases derived from spirosuccinimides and spirohydantoins.
AID545521Anticonvulsant activity in ip dosed mouse assessed as inhibition of PTZ-induced clonic seizure after 0.5 hrs2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis and anticonvulsant activity of N-3-arylamide substituted 5,5-cyclopropanespirohydantoin derivatives.
AID396632Neurotoxicity in Swiss albino mouse assessed as inability of animal to maintain equilibrium on the rod for at least 1 min at 300 mg/kg, ip after 0.5 hrs by rotarod test2008European journal of medicinal chemistry, Dec, Volume: 43, Issue:12
Newer GABA derivatives for the treatment of epilepsy including febrile seizures: a bioisosteric approach.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID128695Time of peak effect activity against maximal electroshock induced seizures1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Synthesis and anticonvulsant activity of 2-benzylglutarimides.
AID382387Neurotoxicity in mouse at 300 mg/kg, ip after 0.5 hrs by rotarod test2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Synthesis and CNS depressant activity of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones.
AID623163Anticonvulsant activity in Sprague-Dawley albino rat assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 50 mg/kg, po after 4 hrs2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Synthesis and anticonvulsant activity of new N-Mannich bases derived from 5-cyclopropyl-5-phenyl- and 5-cyclopropyl-5-(4-chlorophenyl)-imidazolidine-2,4-diones.
AID286858Analgesic activity in Swiss Albino mouse assessed as number of acetic acid-induced writhing per 30 min after 100 mg/kg, ip2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Discovery of 4-aminobutyric acid derivatives possessing anticonvulsant and antinociceptive activities: a hybrid pharmacophore approach.
AID290733Acute neurotoxicity in mouse at 300 mg/kg, ip after 4 hrs by rotarod test2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Synthesis and anticonvulsant activity of 4-(2-(2,6-dimethylphenylamino)-2-oxoethylamino)-N-(substituted)butanamides: a pharmacophoric hybrid approach.
AID1229798Toxicity in ip dosed Swiss mouse assessed as induction of motor performance impairment measured within 60 seconds measured at 0.25 hrs of time to peak effect by Chimney test2015Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
Design, synthesis, and anticonvulsant activity of new hybrid compounds derived from 2-(2,5-dioxopyrrolidin-1-yl)propanamides and 2-(2,5-dioxopyrrolidin-1-yl)butanamides.
AID683949Neurotoxicity in CF-1 albino mouse assessed as motor impairment at 300 mg/kg, ip measured after 4 hrs by rotarod test2012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Synthesis and anticonvulsant activity of new N-Mannich bases derived from 3-(2-fluorophenyl)- and 3-(2-bromophenyl)-pyrrolidine-2,5-diones. Part II.
AID226942Protectivity index is the ratio of TD50 /MES ED50 from Phase-II evaluation1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Functionalized DL-amino acid derivatives. Potent new agents for the treatment of epilepsy.
AID1285357Anticonvulsant activity in ip dosed CD1 albino mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Synthesis, and anticonvulsant activity of new amides derived from 3-methyl- or 3-ethyl-3-methyl-2,5-dioxo-pyrrolidin-1-yl-acetic acids.
AID1161061Neurotoxicity in ip dosed albino CF1 mouse2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Novel fluorinated pyrrolo[1,2-a]pyrazine-2,6-dione derivatives: synthesis and anticonvulsant evaluation in animal models of epilepsy.
AID396628Anticonvulsant activity in Swiss albino mouse assessed as inhibition of subcutaneous picrotoxin-induced seizures at 300 mg/kg, ip administered 30 mins before PIC challenge measured after 4 hrs post PIC challenge2008European journal of medicinal chemistry, Dec, Volume: 43, Issue:12
Newer GABA derivatives for the treatment of epilepsy including febrile seizures: a bioisosteric approach.
AID231426Protective index was calculated (TD50/ED50) in scMET assay in mice after intraperitoneal administration1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Synthesis and anticonvulsant activity of 2-benzylglutarimides.
AID623086Protective index, ratio of TD50 for neurotoxicity in Sprague-Dawley albino rat to ED50 for inhibition of subcutaneous pentylenetetrazole-induced seizures in Sprague-Dawley albino rat2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Synthesis and anticonvulsant activity of new N-Mannich bases derived from 5-cyclopropyl-5-phenyl- and 5-cyclopropyl-5-(4-chlorophenyl)-imidazolidine-2,4-diones.
AID168886Time to peak effect in Rats was evaluated by Neurologic toxicity (rotarod test) in hours by oral administration1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Synthesis and evaluation of N-(phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents.
AID1133859Anticonvulsant activity in mouse assessed as protection against maximal electroshock-induced hindlimb tonic extensor component of seizure at 300 mg/kg, ip after 30 mins by MES test1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Potential long-acting anticonvulsants. 1; Synthesis and activity of succinimides containing an alkylating group at the 2 position.
AID231427Protective index was calculated (TD50/ED50) in scMET assay in mice after oral administration1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Synthesis and anticonvulsant activity of 2-benzylglutarimides.
AID1065342Anticonvulsant activity in ip dosed albino rat assessed as protection against pentylenetetrazole-induced seizure after 0.5 hrs2013European journal of medicinal chemistry, Sep, Volume: 67Design, synthesis and anticonvulsant evaluation of N-(benzo[d]thiazol-2-ylcarbamoyl)-2-methyl-4-oxoquinazoline-3(4H)-carbothioamide derivatives: a hybrid pharmacophore approach.
AID1183240Anticonvulsant activity in albino Wistar rat assessed as protection against subcutaneous pentylenetetrazol-induced seizures at 50 mg/kg, po at 2 hrs2014European journal of medicinal chemistry, Sep-12, Volume: 84Design and synthesis of new of 3-(benzo[d]isoxazol-3-yl)-1-substituted pyrrolidine-2, 5-dione derivatives as anticonvulsants.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID180906The effective dose of compound was tested against maximal electroshock induced seizures after oral administration in rat.1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Synthesis and anticonvulsant activity of 2-benzylglutarimides.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1432536Protection index, ratio of TD50 for motor impairment in ip dosed albino CD1 mouse to ED50 for protection against subcutaneous pentylenetetrazole-induced seizures in ip dosed albino CD1 mouse2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Synthesis and evaluation of anticonvulsant properties of new N-Mannich bases derived from pyrrolidine-2,5-dione and its 3-methyl-, 3-isopropyl, and 3-benzhydryl analogs.
AID1183229Anticonvulsant activity in ip dosed albino Swiss mouse assessed as assessed as protection against subcutaneous pentylenetetrazol-induced seizures at 0.5 hr2014European journal of medicinal chemistry, Sep-12, Volume: 84Design and synthesis of new of 3-(benzo[d]isoxazol-3-yl)-1-substituted pyrrolidine-2, 5-dione derivatives as anticonvulsants.
AID489275Neurotoxicity in Swiss albino mouse at 300 mg/kg, ip after 0.5 hrs2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Novel semicarbazones based 2,5-disubstituted-1,3,4-oxadiazoles: one more step towards establishing four binding site pharmacophoric model hypothesis for anticonvulsant activity.
AID1264978Anticonvulsant activity in ip dosed Swiss albino mouse assessed as reduction of subcutaneous pentylenetetrazole-induced seizure after 0.5 hrs2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis of 2,6-dicarbethoxy-3,5-diaryltetrahydro-1,4-thiazine-1,1-dioxide derivatives as potent anticonvulsant agents.
AID477736Anticonvulsant activity in Swiss albino mouse assessed as inhibition of maximum electric shock-induced motor impairment at 300 mg/kg, ip after 0.5 hrs2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening.
AID1415358Anticonvulsant activity in mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 100 mg/kg, ip measured for 30 mins post pentylenetetrazole challenge at 0.5 hrs after compound dosing relative to control2017MedChemComm, Jan-01, Volume: 8, Issue:1
Design, synthesis and anticonvulsant-analgesic activity of new
AID364287Anticonvulsant activity in mouse at 300 mg/kg, ip after 0.5 hrs by MES test2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
CNS depressant and anticonvulsant activities of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1576057Anticonvulsant activity in mouse assessed as proportion of animals displaying reduction in PTZ-induced clonic seizures at 200 mg/kg, ip administered 45 mins before PTZ stimulation relative to control2019MedChemComm, Aug-01, Volume: 10, Issue:8
Derivatives of a new heterocyclic system - pyrano[3,4-
AID489794Anticonvulsant activity against subcutaneous pentylenetetrazole-induced seizures in Swiss albino mouse at 300 mg/kg, ip after 4 hrs2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Combating oxidative stress in epilepsy: design, synthesis, quantum chemical studies and anticonvulsant evaluation of 1-(substituted benzylidene/ethylidene)-4-(naphthalen-1-yl)semicarbazides.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1285358Neurotoxicity in ip dosed CD1 albino mouse assessed as acute motor impairment by rotarod test2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Synthesis, and anticonvulsant activity of new amides derived from 3-methyl- or 3-ethyl-3-methyl-2,5-dioxo-pyrrolidin-1-yl-acetic acids.
AID1229796Anticonvulsant activity in ip dosed Swiss mouse assessed as protection against seizures measured at 0.25 hrs of time to peak effect by subcutaneous pentylenetetrazole seizure test2015Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
Design, synthesis, and anticonvulsant activity of new hybrid compounds derived from 2-(2,5-dioxopyrrolidin-1-yl)propanamides and 2-(2,5-dioxopyrrolidin-1-yl)butanamides.
AID234828Survival ratio was calculated for determination of dose dependency.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Synthesis and anticonvulsant activity of 1-acyl-2-pyrrolidinone derivatives.
AID136086The cytotoxicity after intraperitoneal administration in mice.1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Synthesis and anticonvulsant activity of 2-benzylglutarimides.
AID516019Anticonvulsant activity in CF1 albino mouse assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip after 4 hrs2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Design, synthesis, and anticonvulsant activity of new N-Mannich bases derived from spirosuccinimides and spirohydantoins.
AID540230Dose normalised AUC in rat after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID1576054Anticonvulsant activity in ip dosed mouse assessed as reduction in PTZ-induced clonic seizures administered 45 mins before PTZ stimulation2019MedChemComm, Aug-01, Volume: 10, Issue:8
Derivatives of a new heterocyclic system - pyrano[3,4-
AID1161074Neurotoxicity in ip dosed 6 Hz current-induced seizure albino CF1 mouse model2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Novel fluorinated pyrrolo[1,2-a]pyrazine-2,6-dione derivatives: synthesis and anticonvulsant evaluation in animal models of epilepsy.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID767979Antimutagenic activity in Vibrio harveyi BB7X assessed as inhibition of 4-nitroquinoline-N-oxide-induced mutation2013European journal of medicinal chemistry, Aug, Volume: 66Synthesis and biological properties of new N-Mannich bases derived from 3-methyl-3-phenyl- and 3,3-dimethyl-succinimides. Part V.
AID1544806Anticonvulsant activity in ip dosed albino mouse model of maximal electroshock-induced seizures assessed as prevention of tonic hind limb extension pretreated for 0.5 hrs followed by 50 mA current-induction for 0.25 secs2019Bioorganic & medicinal chemistry letters, 07-15, Volume: 29, Issue:14
Novel benzothiazole hydrazine carboxamide hybrid scaffolds as potential in vitro GABA AT enzyme inhibitors: Synthesis, molecular docking and antiepileptic evaluation.
AID623091Anticonvulsant activity in po dosed Sprague-Dawley albino rat assessed as time to peak effect2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Synthesis and anticonvulsant activity of new N-Mannich bases derived from 5-cyclopropyl-5-phenyl- and 5-cyclopropyl-5-(4-chlorophenyl)-imidazolidine-2,4-diones.
AID626721Anticonvulsant activity in ip dosed albino Carworth Farms No.1 mouse assessed as time needs to show peak effect for electric-current for 3 secs-induced seizure after 0.25 hrs by 6Hz minimal clonic seizure test2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and anticonvulsant activity of novel 2,6-diketopiperazine derivatives. Part 1: perhydropyrrole[1,2-a]pyrazines.
AID1143181Anticonvulsant activity in ip dosed Swiss albino mouse assessed as protection against pentylenetetrazole-induced seizure measured at the time of peak effect during phase 2 trials2014European journal of medicinal chemistry, Jun-10, Volume: 80Anticonvulsant evaluation of clubbed indole-1,2,4-triazine derivatives: a synthetic approach.
AID122459Time to peak toxicity was evaluated by Maximal electroshock seizure test in hours1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Synthesis and evaluation of N-(phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents.
AID1285347Anticonvulsant activity in CD1 albino mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 100 to 300 mg/kg, ip after 4 hrs2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Synthesis, and anticonvulsant activity of new amides derived from 3-methyl- or 3-ethyl-3-methyl-2,5-dioxo-pyrrolidin-1-yl-acetic acids.
AID122456Time to peak effect in mice was evaluated by Neurologic toxicity (rotarod test) in hours by oral administration1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Synthesis and evaluation of N-(phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents.
AID1304287Anticonvulsant activity against albino Swiss mouse seizure model assessed as time to peak effect at 100 mg/kg, ip2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Design, synthesis and anticonvulsant activity of new hybrid compounds derived from N-phenyl-2-(2,5-dioxopyrrolidin-1-yl)-propanamides and -butanamides.
AID1304290Anticonvulsant activity in albino Swiss mouse assessed as protection against electrically-induced seizure by 6Hz psychomotor seizure test2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Design, synthesis and anticonvulsant activity of new hybrid compounds derived from N-phenyl-2-(2,5-dioxopyrrolidin-1-yl)-propanamides and -butanamides.
AID1285360Protection index, ratio of TD50 for CD1 albino mouse to ED50 for protection against subcutaneous pentylenetetrazole-induced seizures in CD1 albino mouse2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Synthesis, and anticonvulsant activity of new amides derived from 3-methyl- or 3-ethyl-3-methyl-2,5-dioxo-pyrrolidin-1-yl-acetic acids.
AID1720864Protective index, ratio of TD50 for neurotoxicity in ip injected albino mouse to ED50 for anticonvulsant activity in ip injected albino mouse assessed as protection against 50 mA current-induced seizure2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants.
AID626752Protective index, ratio of TD50 for albino Sprague-Dawley rat to ED50 for albino Sprague-Dawley rat by subcutaneous metrazol-induced seizure test2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and anticonvulsant activity of novel 2,6-diketopiperazine derivatives. Part 1: perhydropyrrole[1,2-a]pyrazines.
AID1576086Neurotoxicity in mouse assessed as myorelaxation at 100 to 200 mg/kg, ip measured for 2 mins by rotarod test2019MedChemComm, Aug-01, Volume: 10, Issue:8
Derivatives of a new heterocyclic system - pyrano[3,4-
AID1195115Neurological toxicity in intraperitoneally dosed Albino Swiss CD1 mouse by rotarod test2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
Design, synthesis and biological evaluation of new hybrid anticonvulsants derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide derivatives.
AID637071Neurotoxicity in Kunming mouse assessed as minimal motor impairment at 300 mg/kg, ip after 0.5 hrs by rotarod test2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and anticonvulsant activity of 1-(8-(benzyloxy)quinolin-2-yl)-6-substituted-4,6-diazaspiro[2,4]heptane-5,7-diones.
AID1863982Antiseizure activity against ScPTZ-induced seizure in ip dosed CD-1 mouse model assessed as clonic seizures pretreated for 0.25 hrs and measured after 30 mins by subcutaneous pentylenetetrazole test
AID637072Neurotoxicity in Kunming mouse assessed as minimal motor impairment at 300 mg/kg, ip after 4 hrs by rotarod test2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and anticonvulsant activity of 1-(8-(benzyloxy)quinolin-2-yl)-6-substituted-4,6-diazaspiro[2,4]heptane-5,7-diones.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1720866Anticonvulsant activity in ip injected albino mouse assessed as protection against 50 mA current-induced seizure by maximal electroshock seizure test2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants.
AID290731Acute neurotoxicity in mouse at 300 mg/kg, ip after 0.5 hrs by rotarod test2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Synthesis and anticonvulsant activity of 4-(2-(2,6-dimethylphenylamino)-2-oxoethylamino)-N-(substituted)butanamides: a pharmacophoric hybrid approach.
AID305070Neurotoxicity in Albino mouse at 300 mg/kg, ip after 4 hrs by rotarod test2007Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1
Synthesis and anticonvulsant activity of sulfonamide derivatives-hydrophobic domain.
AID382213Neurotoxicity in ip dosed CF1 albino mouse at 300 mg/kg after 0.5 hr by rotarod test2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Design, synthesis, and anticonvulsant activity of N-phenylamino derivatives of 3,3-dialkyl-pyrrolidine-2,5-diones and hexahydro-isoindole-1,3-diones.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1065347Anticonvulsant activity in po dosed albino rat assessed as protection against pentylenetetrazole-induced seizure after 2 hrs2013European journal of medicinal chemistry, Sep, Volume: 67Design, synthesis and anticonvulsant evaluation of N-(benzo[d]thiazol-2-ylcarbamoyl)-2-methyl-4-oxoquinazoline-3(4H)-carbothioamide derivatives: a hybrid pharmacophore approach.
AID1191599Anticonvulsant activity in intraperitoneally dosed Swiss albino mouse assessed as reduction in clonic seizures after 4 hrs by subcutaneous pentylenetetrazole seizure test2015Bioorganic & medicinal chemistry letters, Mar-01, Volume: 25, Issue:5
Design, synthesis and pharmacological evaluation of N-[4-(4-(alkyl/aryl/heteroaryl)-piperazin-1-yl)-phenyl]-carbamic acid ethyl ester derivatives as novel anticonvulsant agents.
AID516017Anticonvulsant activity in CF1 albino mouse assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip after 0.5 hrs2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Design, synthesis, and anticonvulsant activity of new N-Mannich bases derived from spirosuccinimides and spirohydantoins.
AID136085The cytotoxicity after intraperitoneal administration1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Synthesis and anticonvulsant activity of 2-benzylglutarimides.
AID626719Anticonvulsant activity in ip dosed albino Carworth Farms No.1 mouse assessed as protection against electric-current for 3 secs-induced seizure after 0.25 hrs by 6Hz minimal clonic seizure test2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and anticonvulsant activity of novel 2,6-diketopiperazine derivatives. Part 1: perhydropyrrole[1,2-a]pyrazines.
AID1065318Anticonvulsant activity in ip dosed albino mouse assessed as protection against 6 Hz electroshock-induced seizures after 1 hr2013European journal of medicinal chemistry, Sep, Volume: 67Design, synthesis and anticonvulsant evaluation of N-(benzo[d]thiazol-2-ylcarbamoyl)-2-methyl-4-oxoquinazoline-3(4H)-carbothioamide derivatives: a hybrid pharmacophore approach.
AID545523Neurotoxicity against ip dosed mouse by rotarod test after 0.5 hrs2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Synthesis and anticonvulsant activity of N-3-arylamide substituted 5,5-cyclopropanespirohydantoin derivatives.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1304293Protective index, ratio of TD50 for acute neurotoxicity in albino Swiss mouse to ED50 for anticonvulsant activity in albino Swiss mouse by subcutaneous pentylenetetrazole seizure test2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Design, synthesis and anticonvulsant activity of new hybrid compounds derived from N-phenyl-2-(2,5-dioxopyrrolidin-1-yl)-propanamides and -butanamides.
AID111829Ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 160 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID1183253Neurotoxicity in albino Wistar rat at 300 mg/kg, ip at 4 hrs by rotorod test2014European journal of medicinal chemistry, Sep-12, Volume: 84Design and synthesis of new of 3-(benzo[d]isoxazol-3-yl)-1-substituted pyrrolidine-2, 5-dione derivatives as anticonvulsants.
AID1065340Anticonvulsant activity in ip dosed albino rat assessed as protection against pentylenetetrazole-induced seizure after 4 hrs2013European journal of medicinal chemistry, Sep, Volume: 67Design, synthesis and anticonvulsant evaluation of N-(benzo[d]thiazol-2-ylcarbamoyl)-2-methyl-4-oxoquinazoline-3(4H)-carbothioamide derivatives: a hybrid pharmacophore approach.
AID626714Anticonvulsant activity in ip dosed albino Carworth Farms No.1 mouse assessed as protection against maximal electroshock-induced seizure after 0.25 hrs2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and anticonvulsant activity of novel 2,6-diketopiperazine derivatives. Part 1: perhydropyrrole[1,2-a]pyrazines.
AID1452170Neurotoxicity in ip dosed Albino Swiss CD-1 mouse assessed as induction of motor impairment measured up to 60 secs by chimney test
AID168749Median Effective dose was evaluated by Neurologic toxicity (rotarod test) in Rats by oral administration1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Synthesis and evaluation of N-(phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents.
AID623088Neurotoxicity in oral dosed Sprague-Dawley albino rat assessed as motor impairment by rotarod test2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Synthesis and anticonvulsant activity of new N-Mannich bases derived from 5-cyclopropyl-5-phenyl- and 5-cyclopropyl-5-(4-chlorophenyl)-imidazolidine-2,4-diones.
AID1576062Anticonvulsant activity in mouse assessed as MES-induced clonic seizures at 10 to 100 mg/kg, ip administered 45 mins before electrical stimulation2019MedChemComm, Aug-01, Volume: 10, Issue:8
Derivatives of a new heterocyclic system - pyrano[3,4-
AID382191Anticonvulsant activity in Sprague-Dawley rat assessed as protection against seizure rat at 50 mg/kg, po after 0.25 hr by subcutaneous pentylenetetrazole test2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Design, synthesis, and anticonvulsant activity of N-phenylamino derivatives of 3,3-dialkyl-pyrrolidine-2,5-diones and hexahydro-isoindole-1,3-diones.
AID221087Time of peak effect of activity of compound was measured by both MES and sc Met test in mice1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis and CLOGP correlation of imidooxy anticonvulsants.
AID136515Latency to the onset of generalized clonic epileptic seizures by picrotoxin was measured and evaluated as a percent of the control in mice.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Synthesis and anticonvulsant activity of 1-acyl-2-pyrrolidinone derivatives.
AID122004Neurotoxicity was determined from the rotarod ataxia test for the compound by the intraperitoneal administration.1991Journal of medicinal chemistry, Jun, Volume: 34, Issue:6
Synthesis and anticonvulsant activity of 2-iminohydantoins.
AID1196893Anticonvulsant activity in Kunming mouse assessed as protection against maximal electroshock-induced seizures measured as abolition of hind limb tonic extension spasm at 300 mg/kg, ip after 4 hrs2015European journal of medicinal chemistry, Mar-06, Volume: 92Design, synthesis and pharmacological evaluation of novel N-(2-(1, 1-dimethyl-5, 7-dioxo-4, 6-diazaspiro[2.4]heptan-6-yl)ethyl) sulfonamide derivatives as potential anticonvulsant agents.
AID477352Anticonvulsant activity in ip dosed Swiss albino mouse assessed as inhibition of PTZ-induced motor impairment after 0.5 hrs2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening.
AID489280Anticonvulsant activity against subcutaneous strychnine-induced seizures in ip dosed Wistar rat assessed as minimum effective dose after 0.5 hrs2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Novel semicarbazones based 2,5-disubstituted-1,3,4-oxadiazoles: one more step towards establishing four binding site pharmacophoric model hypothesis for anticonvulsant activity.
AID189460Protective index (TD50/ED50) was determined against scMet induced seizure in rat.1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Synthesis and evaluation of N-(phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents.
AID489284Anticonvulsant activity against subcutaneous pentylenetetrazole-induced seizures in ip dosed Swiss albino mouse assessed as minimum effective dose after 0.5 hrs2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Novel semicarbazones based 2,5-disubstituted-1,3,4-oxadiazoles: one more step towards establishing four binding site pharmacophoric model hypothesis for anticonvulsant activity.
AID626720Protective index, ratio of TD50 for albino Carworth Farms No.1 mouse to ED50 for albino Carworth Farms No.1 mouse by 6Hz minimal clonic seizure test2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and anticonvulsant activity of novel 2,6-diketopiperazine derivatives. Part 1: perhydropyrrole[1,2-a]pyrazines.
AID629169Antiepileptic activity in ip dosed Swiss albino mouse assessed as dose required to protect against subcutaneous pentylenetetrazol-induced clonic seizures after 4 hrs2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Design, synthesis and antiepileptic properties of novel 1-(substituted benzylidene)-3-(1-(morpholino/piperidino methyl)-2,3-dioxoindolin-5-yl)urea derivatives.
AID118788Compound was tested for cognitive activity by measuring retention for passive avoidance learning in mice at dose 10 mg/kg1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Cognition-activating properties of 3-(Aryloxy)pyridines.
AID395117Neurotoxicity in Swiss albino mouse at 300 mg/kg, ip after 4 hrs by rotarod test2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis of some novel N4-(naphtha[1,2-d]thiazol-2-yl)semicarbazides as potential anticonvulsants.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID489798Neurotoxicity in ip dosed Swiss albino mouse assessed as impair in motor coordination at 300 mg/kg, ip after 4 hrs by rotarod test2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Combating oxidative stress in epilepsy: design, synthesis, quantum chemical studies and anticonvulsant evaluation of 1-(substituted benzylidene/ethylidene)-4-(naphthalen-1-yl)semicarbazides.
AID305068Neurotoxicity in Albino mouse at 300 mg/kg, ip after 0.5 hrs by rotarod test2007Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1
Synthesis and anticonvulsant activity of sulfonamide derivatives-hydrophobic domain.
AID487185Anticonvulsant activity in Albino mouse assessed as protection against maximal electric shock-induced seizure at 300 mg/kg, ip after 4 hrs2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Synthesis, anticonvulsant and toxicity screening of newer pyrimidine semicarbazone derivatives.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID113983Anticonvulsant activity was determined by subcutaneous bicuculline test (CD97=2.70 mg/kg) (Phase V Pharmacological Evaluation)1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Functionalized DL-amino acid derivatives. Potent new agents for the treatment of epilepsy.
AID1133870Anticonvulsant activity in ip dosed mouse assessed as protection against metrazole-induced seizures by subcutaneous pentylenetetrazole seizure threshold test1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Potential long-acting anticonvulsants. 1; Synthesis and activity of succinimides containing an alkylating group at the 2 position.
AID628634Neurotoxicity in CF1 albino mouse assessed as motor impairment at 300 mg/kg, ip after 0.5 hrs by rotarod test2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and anticonvulsant properties of new acetamide derivatives of phthalimide, and its saturated cyclohexane and norbornene analogs.
AID489277Anticonvulsant activity against subcutaneous strychnine-induced seizures in Wistar rat at 300 mg/kg, ip after 4 hrs2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Novel semicarbazones based 2,5-disubstituted-1,3,4-oxadiazoles: one more step towards establishing four binding site pharmacophoric model hypothesis for anticonvulsant activity.
AID1191598Anticonvulsant activity in intraperitoneally dosed Swiss albino mouse assessed as reduction in clonic seizures after 0.5 hrs by subcutaneous pentylenetetrazole seizure test2015Bioorganic & medicinal chemistry letters, Mar-01, Volume: 25, Issue:5
Design, synthesis and pharmacological evaluation of N-[4-(4-(alkyl/aryl/heteroaryl)-piperazin-1-yl)-phenyl]-carbamic acid ethyl ester derivatives as novel anticonvulsant agents.
AID683943Anticonvulsant activity in ip dosed CF-1 albino mouse assessed as protection against subcutaneous pentylenetetrazol-induced seizures measured after 4 hrs2012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Synthesis and anticonvulsant activity of new N-Mannich bases derived from 3-(2-fluorophenyl)- and 3-(2-bromophenyl)-pyrrolidine-2,5-diones. Part II.
AID1720867Anticonvulsant activity in albino mouse assessed as pentylenetetrazole-induced seizure2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants.
AID626748Anticonvulsant activity in po dosed albino Sprague-Dawley rat assessed as protection against subcutaneous metrazol-induced seizure after 0.25 hrs2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and anticonvulsant activity of novel 2,6-diketopiperazine derivatives. Part 1: perhydropyrrole[1,2-a]pyrazines.
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1196894Neurotoxicity in Kunming mouse assessed as motor impairment at 300 mg/kg, ip after 0.5 hrs by standardized rotarod test2015European journal of medicinal chemistry, Mar-06, Volume: 92Design, synthesis and pharmacological evaluation of novel N-(2-(1, 1-dimethyl-5, 7-dioxo-4, 6-diazaspiro[2.4]heptan-6-yl)ethyl) sulfonamide derivatives as potential anticonvulsant agents.
AID516022Anticonvulsant activity in ip dosed CF1 albino mouse assessed as dose required to protect against subcutaneous pentylenetetrazole-induced seizures after 4 hrs2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Design, synthesis, and anticonvulsant activity of new N-Mannich bases derived from spirosuccinimides and spirohydantoins.
AID190104The cytotoxicity after intraperitoneal administration in rat.1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Synthesis and anticonvulsant activity of 2-benzylglutarimides.
AID128037Compound was tested for anticonvulsant activity against bicuculline-induced clonic seizures in mice at 2.7 mg/kg sc1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
2-Phenyl-3H-imidazo[4,5-b]pyridine-3-acetamides as non-benzodiazepine anticonvulsants and anxiolytics.
AID128040Compound was tested for anticonvulsant activity against pentylenetetrazole-induced clonic seizures in mice at 80 mg/kg sc1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
2-Phenyl-3H-imidazo[4,5-b]pyridine-3-acetamides as non-benzodiazepine anticonvulsants and anxiolytics.
AID1452168Anticonvulsant activity in ip dosed Albino Swiss CD-1 mouse assessed as protection against 32 mA current-induced seizure treated up to 2 hrs prior to 6-Hz current induction measured at time to peak effect
AID727991Antiepileptic activity in ip dosed Swiss albino mouse assessed as protection against scPTZ-induced seizures after 0.5 hrs2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Novel limonene and citral based 2,5-disubstituted-1,3,4-oxadiazoles: a natural product coupled approach to semicarbazones for antiepileptic activity.
AID113905Median effective dose was evaluated by Maximal electroshock seizure test through intraperitoneal administration1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Synthesis and evaluation of N-(phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID290724Anticonvulsant activity against subcutaneous pentylenetetrazole-induced seizure in mouse at 100 mg/kg, ip after 0.5 hrs2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Synthesis and anticonvulsant activity of 4-(2-(2,6-dimethylphenylamino)-2-oxoethylamino)-N-(substituted)butanamides: a pharmacophoric hybrid approach.
AID396413Anticonvulsant activity in Swiss albino mouse assessed as inhibition of maximal electroshock-induced seizures at 300 mg/kg, ip administered 30 mins before electroshock measured after 0.5 hrs post electroshock2008European journal of medicinal chemistry, Dec, Volume: 43, Issue:12
Newer GABA derivatives for the treatment of epilepsy including febrile seizures: a bioisosteric approach.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1143163Anticonvulsant activity in Swiss albino mouse assessed as protection against maximal electroshock-induced tonic-clonic seizure spread measured at 300 mg/kg, ip after 4 hrs by MES test2014European journal of medicinal chemistry, Jun-10, Volume: 80Anticonvulsant evaluation of clubbed indole-1,2,4-triazine derivatives: a synthetic approach.
AID626657Protective index, ratio of TD50 for albino Carworth Farms No.1 mouse to ED50 for albino Carworth Farms No.1 mouse by subcutaneous metrazol-induced seizure test2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis and anticonvulsant activity of novel 2,6-diketopiperazine derivatives. Part 1: perhydropyrrole[1,2-a]pyrazines.
AID113970Anticonvulsant activity was determined by by subcutaneous strychnine test (CD97=1.20 mg/kg) (Phase V Pharmacological Evaluation); Maximum protection: 50% at 55-100 mg/kg1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Functionalized DL-amino acid derivatives. Potent new agents for the treatment of epilepsy.
AID134733Median lethal dose was measured after 24 hr.1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Synthesis and anticonvulsant activity of 2-benzylglutarimides.
AID118792Compound was tested for cognitive activity by measuring retention for passive avoidance learning in mice at dose 40 mg/kg1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Cognition-activating properties of 3-(Aryloxy)pyridines.
AID382214Neurotoxicity in ip dosed CF1 albino mouse at 300 mg/kg after 4 hrs by rotarod test2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
Design, synthesis, and anticonvulsant activity of N-phenylamino derivatives of 3,3-dialkyl-pyrrolidine-2,5-diones and hexahydro-isoindole-1,3-diones.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1135320Anticonvulsant activity in ip dosed albino CD-1 mouse assessed as threshold ratio for pentylenetetrazole-induced clonic seizures at 0.5 time TD50 measured at time of peak effect relative to saline-treated control1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
3,4-Methylenedioxyphenyl-, isopropylidenedioxyphenyl-, and benzyl-substituted chiral 2-aminosuccinimides and 3-aminopyrrolidines. Stereoselective investigations of potential anti-parkinsonian, antipsychotic, and anticonvulsant activities.
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID286842Anticonvulsant activity in Swiss Albino mouse at 300 mg/kg, ip after 0.5 hr by scPTZ test2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Discovery of 4-aminobutyric acid derivatives possessing anticonvulsant and antinociceptive activities: a hybrid pharmacophore approach.
AID1544807Anticonvulsant activity in ip dosed albino mouse model of maximal electroshock-induced seizures assessed as prevention of tonic hind limb extension pretreated for 4 hrs followed by 50 mA current-induction for 0.25 secs2019Bioorganic & medicinal chemistry letters, 07-15, Volume: 29, Issue:14
Novel benzothiazole hydrazine carboxamide hybrid scaffolds as potential in vitro GABA AT enzyme inhibitors: Synthesis, molecular docking and antiepileptic evaluation.
AID623228Anticonvulsant activity in CF1 albino mouse assessed as protection against maximal electroshock-induced seizures at 300 mg/kg, ip after 0.5 hrs2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Synthesis and anticonvulsant activity of new N-Mannich bases derived from 5-cyclopropyl-5-phenyl- and 5-cyclopropyl-5-(4-chlorophenyl)-imidazolidine-2,4-diones.
AID511975Neurotoxicity in Kunming rat assessed as minimum motor impairment at 30 mg/kg, po after 4 hrs by rotarod test2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis and anticonvulsant activity of new 6-methyl-1-substituted-4,6-diazaspiro[2.4]heptane-5,7-diones.
AID780692Protective index, ratio of TD50 for albino mouse minimal clonic seizure model to ED50 for albino mouse assessed as protection against 6 Hz psychomotor seizure2013Bioorganic & medicinal chemistry letters, Nov-15, Volume: 23, Issue:22
Structure-activity relationships of the aromatic site in novel anticonvulsant pyrrolo[1,2-a]pyrazine derivatives.
AID1264979Anticonvulsant activity in ip dosed Swiss albino mouse assessed as reduction of subcutaneous pentylenetetrazole-induced seizure after 4 hrs2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis of 2,6-dicarbethoxy-3,5-diaryltetrahydro-1,4-thiazine-1,1-dioxide derivatives as potent anticonvulsant agents.
AID516046Protection index, ratio of TD50 for Sprague-Dawley rat by rotarod test to ED50 for Sprague-Dawley rat by maximal electroshock test2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Design, synthesis, and anticonvulsant activity of new N-Mannich bases derived from spirosuccinimides and spirohydantoins.
AID1195111Anticonvulsant activity in intraperitoneally dosed Albino Swiss CD1 mouse assessed as time to peak effect by maximal electroshock test2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
Design, synthesis and biological evaluation of new hybrid anticonvulsants derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide derivatives.
AID1191607Neurological toxicity in Swiss albino mouse assessed as motor impairment at at 300 mg/kg, ip after 4 hrs by rotarod test2015Bioorganic & medicinal chemistry letters, Mar-01, Volume: 25, Issue:5
Design, synthesis and pharmacological evaluation of N-[4-(4-(alkyl/aryl/heteroaryl)-piperazin-1-yl)-phenyl]-carbamic acid ethyl ester derivatives as novel anticonvulsant agents.
AID53026Compound was evaluated for effective dose by maximal electroshock test after intraperitoneal administration of the compound.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and anticonvulsant activity of imidooxy derivatives.
AID637066Anticonvulsant activity in ip dosed Kunming mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizure after 4 hrs2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and anticonvulsant activity of 1-(8-(benzyloxy)quinolin-2-yl)-6-substituted-4,6-diazaspiro[2,4]heptane-5,7-diones.
AID1711735Protection index, ratio of TD50 for neurotoxicity in ip dosed mouse to ED50 for anticonvulsant activity in ip dosed mouse measured after 0.25 hrs by 6 Hz limbic seizure test2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Synthesis and evaluation of anticonvulsant properties of new N-Mannich bases derived from 3-(1-phenylethyl)- and 3-benzyl-pyrrolidine-2,5-dione.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,017)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990506 (49.75)18.7374
1990's134 (13.18)18.2507
2000's140 (13.77)29.6817
2010's188 (18.49)24.3611
2020's49 (4.82)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 70.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index70.69 (24.57)
Research Supply Index7.03 (2.92)
Research Growth Index4.49 (4.65)
Search Engine Demand Index125.22 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (70.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials37 (3.38%)5.53%
Reviews94 (8.58%)6.00%
Case Studies95 (8.67%)4.05%
Observational1 (0.09%)0.25%
Other869 (79.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (12)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Parallel-group,Placebo-controlled, Double-blind Clinical Trial to Evaluate the Efficacy and Safety of Ethosuximide in Chinese Patients With Treatment-Resistant Depression. [NCT03887624]Early Phase 116 participants (Actual)Interventional2019-05-21Terminated(stopped due to Participates could not stand the side effects)
Assessment of the Effectiveness of Ethosuximide in the Treatment of Peripheral Neuropathic Pain. [NCT02100046]Phase 2114 participants (Actual)Interventional2014-03-31Completed
Evaluation of the Efficacy and Tolerance of Ethosuximide in the Treatment of Abdominal Pain Associated With Irritable Bowel Syndrome [NCT02973542]Phase 2162 participants (Actual)Interventional2018-04-30Active, not recruiting
A Randomised Controlled Trial of the Ketogenic Diet in the Treatment of Epilepsy in Children Under the Age of Two Years [NCT02205931]Phase 4160 participants (Anticipated)Interventional2015-01-31Recruiting
A Single Centre. Parallel-Group, Double-Blinded, Randomized, Placebo-Controlled Pilot Clinical Trial on Ethosuximide for the Treatment of Complex Regional Pain Syndrome (CRPS) [NCT00689585]Phase 24 participants (Actual)Interventional2008-09-30Terminated(stopped due to Recruitment difficult and enrolment low: decision was made to stop the study.)
Evaluation of the Efficacy and Tolerance of Low Doses of Ethosuximide in the Treatment of Peripheral Neuropathic Pain [NCT04431778]Phase 264 participants (Anticipated)Interventional2020-11-01Recruiting
A Comparative Study to Assess Safety and Effectiveness of Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome [NCT04217733]Phase 360 participants (Anticipated)Interventional2019-11-01Recruiting
Pharmacologic and Genetic Evaluation of a C. Elegans Model for Migraine [NCT01122381]Phase 1/Phase 25 participants (Actual)Interventional2011-12-31Terminated(stopped due to poor recruitment)
A Prospective, Case-control Evaluation of Ketogenic Dietary Therapy for New-onset Childhood Absence Epilepsy [NCT04274179]Phase 340 participants (Anticipated)Interventional2020-08-10Recruiting
Population Pharmacokinetics of Antiepileptic in Pediatrics [NCT03196466]1,000 participants (Anticipated)Observational2017-06-19Recruiting
A Randomised Double-blind Placebo-controlled Trial of the Safety and Efficacy of Ethosuximide 250mg Capsules for the Management of Chemotherapy Induced Painful Peripheral Neuropathy [NCT01278004]Phase 215 participants (Actual)Interventional2010-05-31Completed
Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study [NCT00088452]Phase 3453 participants (Actual)Interventional2004-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00088452 (3) [back to overview]Number of Participants With Attention Deficit as Measured by the Confidence Index of the CPT-II and the K-CPT
NCT00088452 (3) [back to overview]Number of Participants With Freedom From Treatment Failure at 12 Months of Double Blind Therapy
NCT00088452 (3) [back to overview]Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy

Number of Participants With Attention Deficit as Measured by the Confidence Index of the CPT-II and the K-CPT

A Confidence Index of 0.60 or higher on the Conners' Continuous Performance Test at the visit at 16 or 20 weeks or at an earlier visit when treatment was discontinued (as long as the discontinuation occurred 1 month or more after the baseline visit and was not due to intolerable adverse events). A Confidence Index of 0.60 corresponds to a 60% probability that the child has clinical attention deficit disorder. (NCT00088452)
Timeframe: First 16-20 weeks of double blind therapy

InterventionParticipants (Count of Participants)
Ethosuximide35
Lamotrigine25
Valproic Acid52

[back to top]

Number of Participants With Freedom From Treatment Failure at 12 Months of Double Blind Therapy

Treatment failure was defined as persistence of absence seizures at 12 months of double blind therapy, a generalized tonic-clonic seizure at any time, excessive drug-related systemic toxicity, a moderately severe rash (possibly drug-related), pancreatitis, or increase in the body-mass index of at least 3.0 from baseline, dose-limiting toxicity after a single downward dose modification, or withdrawal initiated by the parent or physician. (NCT00088452)
Timeframe: First 12 months of double blind therapy

InterventionParticipants (Count of Participants)
Ethosuximide70
Lamotrigine31
Valproic Acid64

[back to top]

Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy

Treatment failure was defined as persistence of absence seizures at week 16 or week 20, a generalized tonic-clonic seizure at any time, excessive drug-related systemic toxicity, a moderately severe rash (possibly drug-related), pancreatitis, or increase in the body-mass index of at least 3.0 from baseline, dose-limiting toxicity after a single downward dose modification, or withdrawal initiated by the parent or physician. (NCT00088452)
Timeframe: First 16-20 weeks of double blind therapy

InterventionParticipants (Count of Participants)
Ethosuximide81
Lamotrigine43
Valproic Acid85

[back to top]